WHO Drug Information, Vol. 25, No. 1, 2011                                                Recommended INN: List 65



International Nonproprietary Names for
Pharmaceutical Substances (INN)
RECOMMENDED International Nonproprietary Names:
List 65
Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended
International Nonproprietary Names for Pharmaceutical Substances [Off. Rec. Wld Health Org., 1955, 60, 3 (Resolution
EB15.R7); 1969, 173, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are
selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended
International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or
pharmacy.
Lists of Proposed (1–101) and Recommended (1–62) International Nonproprietary Names can be found in Cumulative List
No. 13, 2009 (available in CD-ROM only).



Dénominations communes internationales
des Substances pharmaceutiques (DCI)
Dénominations communes internationales RECOMMANDÉES:
Liste 65
Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de
Dénominations communes internationales recommandées pour les Substances pharmaceutiques [Actes off. Org. mond.
Santé, 1955, 60, 3 (résolution EB15.R7); 1969, 173, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)]
les dénominations ci-dessous sont choisies par l’Organisation mondiale de la Santé en tant que dénominations communes
internationales recommandées. L’inclusion d’une dénomination dans les listes de DCI recommandées n’implique aucune
recommandation en vue de l’utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d’autres listes de Dénominations communes internationales proposées (1–101) et recommandées (1–62) dans
la Liste récapitulative No. 13, 2009 (disponible sur CD-ROM seulement).



Denominaciones Comunes Internacionales
para las Sustancias Farmacéuticas (DCI)
Denominaciones Comunes Internacionales RECOMENDADAS:
Lista 65
De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes
Internacionales Recomendadas para las Sustancias Farmacéuticas [Act. Of. Mund. Salud, 1955, 60, 3 (Resolución
EB15.R7); 1969, 173, 10 (Resolución EB43.R9); Résolution EB115.R4 (EB115/2005/REC/1) EB115.R4
(EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han
sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en
las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la
sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–101) y Recomendadas (1–62) se encuentran
reunidas en Cumulative List No. 13, 2009 (disponible sólo en CD-ROM).


                                                                                                                  49
Recommended INN: List 65                                                     WHO Drug Information, Vol. 25, No. 1, 2011




 Latin, English, French, Spanish:
 Recommended INN                    Chemical name or description; Molecular formula; Graphic formula

 DCI Recommandée                    Nom chimique ou description; Formule brute; Formule développée

 DCI Recomendada                    Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada




 amuvatinibum
 amuvatinib                                N-[(1,3-benzodioxol-5-yl)methyl]-4-([1]benzofuro[3,2-d]pyrimidin-
                                           4-yl)piperazine-1-carbothioamide

 amuvatinib                                N-[(1,3-benzodioxol-5-yl)méthyl]-4-([1]benzofuro[3,2-d]pyrimidin-
                                           4-yl)pipérazine-1-carbothioamide

 amuvatinib                                N-[(1,3-benzodioxol-5-il)metil]-4-([1]benzofuro[3,2-d]pirimidin-
                                           4-il)piperazina-1-carbotioamida

                                           C23H21N5O3S

                                                       N       N

                                                                                                     O
                                                                   N
                                                                                  H
                                                           O             N        N
                                                                                                     O

                                                                             S




 anagliptinum
 anagliptin                                N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-
                                           2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide

 anagliptine                               N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoéthyl}amino)-
                                           2-méthylpropyl]-2-méthylpyrazolo[1,5-a]pyrimidine-6-carboxamide

 anagliptina                               N-[2-({2-[(2S)-2-cianopirrolidin-1-il]-2-oxoetil}amino)-2-metilpropil]-
                                           2-metilpirazolo[1,5-a]pirimidina-6-carboxamida

                                           C19H25N7O2

                                                               O                      O       H CN
                                                                              H
                                                                              N
                                                   N               N                      N
                                                                   H
                                                                       H3C   CH3
                                                       N
                                                       N
                                            H 3C




50
WHO Drug Information, Vol. 25, No. 1, 2011                                                 Recommended INN: List 65


 atecegatranum
 atecegatran                                 (2S)-N-[(4-carbamimidoylphenyl)methyl]-1-{(2R)-2-[3-chloro-
                                             5-(difluoromethoxy)phenyl]-2-hydroxyacetyl}azetidine-2-carboxamide

 atécégatran                                 (2S)-N-[(4-carbamimidoylphényl)méthyl]-1-{(2R)-2-[3-chloro-
                                             5-(difluorométhoxy)phényl]-2-hydroxyacétyl}azétidine-2-carboxamide

 atecegatrán                                 (2S)-N-[(4-carbamimidoilfenil)metil]-1-{(2R)-2-[3-cloro-
                                             5-(difluorometoxi)fenil]-2-hidroxiacetil}azetidina-2-carboxamida

                                             C21H21ClF2N4O4

                                                    NH

                                             H2 N                                   H OH
                                                                    H
                                                                    N           N                  Cl
                                                                            H
                                                                        O           O

                                                                                           O       F

                                                                                               F

 avibactamum
 avibactam                                   (1R,2S,5R)-7-oxo-6-sulfooxy-1,6-diazabicyclo[3.2.1]octane-
                                             2-carboxamide

 avibactam                                   (1R,2S,5R)-7-oxo-6-sulfooxy-1,6-diazabicyclo[3.2.1]octane-
                                             2-carboxamide

 avibactam                                   (1R,2S,5R)-7-oxo-6-sulfooxi-1,6-diazabiciclo[3.2.1]octano-
                                             2-carboxamida

                                             C7H11N3O6S

                                                                    O
                                                                H
                                                     O
                                                            N           NH2

                                              O O   N
                                                S O
                                             HO             H

 bavisantum
 bavisant                                    (4-cyclopropylpiperazin-1-yl}){4-[(morpholin-
                                             4-yl)methyl]phenyl}methanone

 bavisant                                    (4-cyclopropylpipérazin-1-yl){4-[(morpholin-
                                             4-yl)méthyl]phényl}méthanone

 bavisant                                    (4-ciclopropilpiperazin-1-il){4-[(morfolin-4-il)metil]fenil}metanona

                                             C19H27N3O2

                                                                    O

                                             O                          N
                                                    N                           N




                                                                                                                    51
Recommended INN: List 65                                WHO Drug Information, Vol. 25, No. 1, 2011


 bedaquilinum
 bedaquiline                 (1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-
                             2-(naphthalen-1-yl)-1-phenylbutan-2-ol

 bédaquiline                 (1R,2S)-1-(6-bromo-2-méthoxyquinoléin-3-yl)-4-(diméthylamino)-
                             2-(naphtalén-1-yl)-1-phénylbutan-2-ol

 bedaquilina                 (1R,2S)-1-(6-bromo-2-metoxiquinolein-3-il)-4-(dimetilamino)-
                             2-(naftalen-1-il)-1-fenilbutan-2-ol

                             C32H31BrN2O2

                                          N      OCH3
                                                  H
                             Br
                                            HO

                                                            CH3
                                                        N
                                                        CH3



 brentuximabum vedotinum #
 brentuximab vedotin         immunoglobulin G1-kappa auristatin E conjugate, anti-[Homo
                             sapiens TNFRSF8 (tumor necrosis factor receptor superfamily
                             member 8, KI-1, CD30)], chimeric monoclonal antibody conjugated
                             to auristatin E; gamma1 heavy chain (1-446) [Mus musculus VH
                             (IGHV1-84*02 -(IGHD)-IGHJ3*01) [8.8.10] (1-117) -Homo sapiens
                             IGHG1*01 CH3 K130>del (118-446)], (220-218')-disulfide (if not
                             conjugated) with kappa light chain (1'-218') [Mus musculus V-KAPPA
                             (IGKV3-4*01 -IGKJ1*01) [10.3.9] (1'-111') -Homo sapiens IGKC*01
                             (112'-218')]; (226-226'')-disulfide dimer; conjugated, on an average
                             of 3 to 5 cysteinyl, to monomethylauristatin E (MMAE), via a
                             maleimidecaproyl-valyl-citrullinyl-p-aminobenzylcarbamate (mc-val-
                             cit-PABC) linker
                             For the vedotin part, please refer to the document "INN for
                             pharmaceutical substances: Names for radicals, groups and
                             others"*.

 brentuximab védotine        immunoglobuline G1-kappa conjuguée à l'auristatine E, anti-[Homo
                             sapiens TNFRSF8 (membre 8 de la superfamille des récepteurs du
                             facteur de nécrose tumorale, KI-1, CD30)], anticorps monoclonal
                             chimérique conjugué à l'auristatine E;
                             chaîne lourde gamma1 (1-446) [Mus musculus VH (IGHV1-84*02 -
                             (IGHD)-IGHJ3*01) [8.8.10] (1-117) -Homo sapiens IGHG1*01 CH3
                             K130>del (118-446)], (220-218')-disulfure (si non conjugué) avec la
                             chaîne légère kappa (1'-218') [Mus musculus V-KAPPA (IGKV3-4*01
                             -IGKJ1*01) [10.3.9] (1'-111') -Homo sapiens IGKC*01 (112'-218')];
                             dimère (226-226'')-disulfure; conjugué, sur 3 à 5 cystéinyl en
                             moyenne, au monométhylauristatine E (MMAE), via un linker
                             maléimidécaproyl-valyl-citrullinyl-p-aminobenzylcarbamate (mc-val-
                             cit-PABC)
                             Pour la partie védotine, veuillez vous référer au document "INN for
                             pharmaceutical substances: Names for radicals, groups and
                             others"*.




52
WHO Drug Information, Vol. 25, No. 1, 2011                                                            Recommended INN: List 65


 brentuximab vedotina                        inmunoglobulina G1-kappa conjugada con auristatina E, anti-[Homo
                                             sapiens TNFRSF8 (miembro 8 de la superfamilia de los receptores
                                             del factor de necrosis tumoral, KI-1, CD30)], anticuerpo monoclonal
                                             quimérico conjugado con auristatina E;
                                             cadena pesada gamma1 (1-446) [Mus musculus VH (IGHV1-84*02 -
                                             (IGHD)-IGHJ3*01) [8.8.10] (1-117) -Homo sapiens IGHG1*01 CH3
                                             K130>del (118-446)], (220-218')-disulfuro (si non está conjugado)
                                             con la cadena ligera kappa (1'-218') [Mus musculus V-KAPPA
                                             (IGKV3-4*01 -IGKJ1*01) [10.3.9] (1'-111') -Homo sapiens IGKC*01
                                             (112'-218')]; dimero (226-226'')-disulfuro; conjugado, en 3 a 5
                                             residuos cisteinil en término medio, con monometilauristatina E
                                             (MMAE), mediante un conector maleimidecaproil-valil-citrulinil-p-
                                             aminobenzilcarbamato (mc-val-cit-PABC)
                                             Por la parte vedotina, por favor, vaya al documento "INN for
                                             pharmaceutical substances: Names for radicals, groups and
                                             others"*.


                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             QIQLQQSGPE VVKPGASVKI SCKASGYTFT                  DYYITWVKQK       PGQGLEWIGW        50
                                             IYPGSGNTKY NEKFKGKATL TVDTSSSTAF                  MQLSSLTSED       TAVYFCANYG       100
                                             NYWFAYWGQG TQVTVSAAST KGPSVFPLAP                  SSKSTSGGTA       ALGCLVKDYF       150
                                             PEPVTVSWNS GALTSGVHTF PAVLQSSGLY                  SLSSVVTVPS       SSLGTQTYIC       200
                                             NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP                  APELLGGPSV       FLFPPKPKDT       250
                                             LMISRTPEVT CVVVDVSHED PEVKFNWYVD                  GVEVHNAKTK       PREEQYNSTY       300
                                             RVVSVLTVLH QDWLNGKEYK CKVSNKALPA                  PIEKTISKAK       GQPREPQVYT       350
                                             LPPSRDELTK NQVSLTCLVK GFYPSDIAVE                  WESNGQPENN       YKTTPPVLDS       400
                                             DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE                  ALHNHYTQKS       LSLSPG           446

                                             Light chain / Chaîne légère / Cadena ligera
                                             DIVLTQSPAS LAVSLGQRAT ISCKASQSVD                  FDGDSYMNWY       QQKPGQPPKV 50
                                             LIYAASNLES GIPARFSGSG SGTDFTLNIH                  PVEEEDAATY       YCQQSNEDPW 100
                                             TFGGGTKLEI KRTVAAPSVF IFPPSDEQLK                  SGTASVVCLL       NNFYPREAKV 150
                                             QWKVDNALQS GNSQESVTEQ DSKDSTYSLS                  STLTLSKADY       EKHKVYACEV 200
                                             THQGLSSPVT KSFNRGEC                                                           218

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H 22-96 144-200              261-321  367-425
                                                      22''-96'' 144''-200'' 261''-321'' 367''-425''
                                             Intra-L 23'-92'      138'-198'
                                                      23'''-92''' 138'''-198'''
                                             Inter-H-L * 220-218' 220''-218'''
                                             Inter-H-H * 226-226'' 229-229''
                                             *Two or three of the inter-chain disulfide bridges are not present, the antibody being
                                             conjugated to an average of 3 to 5 drug linkers each via a thioether bond.
                                             * Deux ou trois des ponts disulfure ne sont pas présents, l'anticorps étant conjugué à
                                             une moyenne de 3 à 5 linker-principe actif chacun via une liaison thioéther.
                                             * Faltan dos o tres puentes disulfuro inter-catenarios por estar el anticuerpo conjugado,
                                             con sendos enlaces tioéter, a una media de 3 a 5 conectores de principio activo

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             297, 297''




 cenicrivirocum
 cenicriviroc                                8-{4-[2-(butoxy)ethoxy]phenyl}-1-(2-methylpropyl)-N-(4-{(S)-[(1-
                                             propyl-1H-imidazol-5-yl)methyl]sulfinyl}phenyl)-1,2,3,4-tetrahydro-
                                             1-benzazocine-5-carboxamide

 cénicriviroc                                8-{4-[2-(butoxy)éthoxy]phényl}-1-(2-méthylpropyl)-N-(4-{(S)-[(1-
                                             propyl-1H-imidazol-5-yl)méthyl]sulfinyl}phényl)-1,2,3,4-tétrahydro-
                                             1-benzazocine-5-carboxamide

 cenicriviroc                                8-{4-[2-(butoxi)etoxi]fenil}-1-(2-metilpropil)-N-(4-{(S)-[(1-propil-
                                             1H-imidazol-5-il)metil]sulfinil}fenil)-1,2,3,4-tetrahidro-1-benzazocina-
                                             5-carboxamida




                                                                                                                                           53
Recommended INN: List 65                                    WHO Drug Information, Vol. 25, No. 1, 2011


                           C41H52N4O4S

                                                     H3 C                                  H3C

                                                     H3C           N
                                     CH3                                                   O       N
                                                                                                       N
                                                                                           S


                           O                                                       N
                                         O                                         H
                                                                       O


 cobicistatum
 cobicistat                (1,3-thiazol-5-yl)methyl (5S,8R,11R)-8,11-dibenzyl-2-methyl-
                           5-[2-(morpholin-4-yl)ethyl]-1-[2-(propan-2-yl)-1,3-thiazol-4-yl]-
                           3,6-dioxo-2,4,7,12-tetraazatridecan-13-oate

 cobicistat                (5S,8R,11R)-8,11-dibenzyl-2-méthyl-5-[2-(morpholin-4-yl)éthyl]-
                           1-[2-(propan-2-yl)-1,3-thiazol-4-yl]-3,6-dioxo-2,4,7,12-
                           tétraazatridécan-13-oate de (1,3-thiazol-5-yl)méthyle

 cobicistat                (5S,8R,11R)-8,11-dibencil-2-metil-5-[2-(morfolin-4-il)etil]-
                           1-[2-(propan-2-il)-1,3-tiazol-4-il]-3,6-dioxo-2,4,7,12-tetraazatridecan-
                           13-oato de (1,3-tiazol-5-il)metilo

                           C40H53N7O5S2

                                                      O


                                                               N

                                                      O            H                   H       O
                                                                           H
                           H3C           N                                 N                               S
                                                 N         N                               N       O
                                                           H                               H
                                                 CH3               O               H
                           H3C           S                                                                 N




 crizotinibum
 crizotinib                3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-
                           1H-pyrazol-4-yl]pyridin-2-amine

 crizotinib                3-[(1R)-1-(2,6-dichloro-3-fluorophényl)éthoxy]-5-[1-(pipéridin-4-yl)-
                           1H-pyrazol-4-yl]pyridin-2-amine

 crizotinib                3-[(1R)-1-(2,6-dicloro-3-fluorofenil)etoxi]-5-[1-(piperidin-4-il)-
                           1H-pirazol-4-il]piridin-2-amina

                           C21H22Cl2FN5O

                                             N       NH2
                                                      H CH3 Cl
                                                                               F
                                                     O
                                 N
                                     N
                                                          Cl



                           HN




54
WHO Drug Information, Vol. 25, No. 1, 2011                                                 Recommended INN: List 65


 dacomitinibum
 dacomitinib                                 (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-
                                             6-yl}-4-(piperidin-1-yl)but-2-enamide

 dacomitinib                                 (2E)-N-{4-[(3-chloro-4-fluorophényl)amino]-7-méthoxyquinazolin
                                             -6-yl}-4-(pipéridin-1-yl)but-2-énamide

 dacomitinib                                 (2E)-N-{4-[(3-cloro-4-fluorofenil)amino]-7-metoxiquinazolin-6-il}-
                                             4-(piperidin-1-il)but-2-enamida

                                             C24H25ClFN5O2

                                                                 H3CO            N

                                                                                      N
                                                                  HN
                                                   N                            HN        Cl
                                                                        O

                                                                                          F



 dexpramipexolum
                                                    6
 dexpramipexole                              (6R)-N -propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
                                                    6
 dexpramipexole                              (6R)-N -propyl-4,5,6,7-tétrahydro-1,3-benzothiazole-2,6-diamine
                                                    6
 dexpramipexol                               (6R)-N -propil-4,5,6,7-tetrahidro-1,3-benzotiazol-2,6-diamina

                                             C10H17N3S

                                                             H
                                                                            S
                                                        HN
                                                                                NH2
                                                                            N
                                             H3C



 drozitumabum #
 drozitumab                                  immunoglobulin G1-lambda, anti-[Homo sapiens TNFRSF10B
                                             (tumor necrosis factor receptor superfamily member 10B, DR5,
                                             death receptor 5, TRAIL-R2, TNF-related apoptosis-inducing ligand
                                             receptor 2, TR-2, CD262)], Homo sapiens monoclonal antibody;
                                             gamma1 heavy chain (1-451) [Homo sapiens VH (IGHV3-20*01
                                             (91.80%) -(IGHD)-IGHJ2*01 R120>K, L123>T) [8.8.14] (1-121) -
                                             IGHG1*03 CH1 R120>K (122-451)], (224-212')-disulfide with lambda
                                             light chain (1'-213') [Homo sapiens V-LAMBDA (IGLV3-19*01
                                             (96.80%) -IGLJ3*01) [6.3.11] (1'-107') -IGLC3*03 (108'-213')]; (230-
                                             230'':233-233'')-bisdisulfide dimer

 drozitumab                                  immunoglobuline G1-lambda, anti-[Homo sapiens TNFRSF10B
                                             (membre 10B de la superfamille des récepteurs du facteur de
                                             nécrose tumorale, DR5, death receptor 5, TRAIL-R2, récepteur 2 du
                                             ligand inducteur d'une apoptose liée au TNF, TR-2, CD262)], Homo
                                             sapiens anticorps monoclonal;
                                             chaîne lourde gamma1 (1-451) [Homo sapiens VH (IGHV3-20*01
                                             (91.80%) -(IGHD)-IGHJ2*01 R120>K, L123>T) [8.8.14] (1-121) -
                                             IGHG1*03 CH1 R120>K (122-451)], (224-212')-disulfure avec la
                                             chaîne légère lambda (1'-213') [Homo sapiens V-LAMBDA (IGLV3-
                                             19*01 (96.80%) -IGLJ3*01) [6.3.11] (1'-107') -IGLC3*03 (108'-213')];
                                             dimère (230-230'':233-233'')-bisdisulfure




                                                                                                                    55
Recommended INN: List 65                                    WHO Drug Information, Vol. 25, No. 1, 2011


 drozitumab                inmunoglobulina G1-lambda, anti-[Homo sapiens TNFRSF10B
                           (miembro 10B de la superfamilia de receptores del factor de
                           necrosis tumoral, DR5, receptor de muerte 5, TRAIL-R2, receptor 2
                           del ligando inductor de la apoptosis de la familiaTNF, TR-2,
                           CD262)], anticuerpo monoclonal de Homo sapiens ;
                           cadena pesada gamma1 (1-451) [Homo sapiens VH (IGHV3-20*01
                           (91.80%) -(IGHD)-IGHJ2*01 R120>K, L123>T) [8.8.14] (1-121) -
                           IGHG1*03 CH1 R120>K (122-451)], (224-212')-disulfuro con la
                           cadena ligera lambda (1'-213') [Homo sapiens V-LAMBDA (IGLV3-
                           19*01 (96.80%) -IGLJ3*01) [6.3.11] (1'-107') -IGLC3*03 (108'-213')];
                           dímero (230-230'':233-233'')-bisdisulfuro


                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLVQSGGG VERPGGSLRL SCAASGFTFD                  DYAMSWVRQA       PGKGLEWVSG        50
                           INWQGGSTGY ADSVKGRVTI SRDNAKNSLY                  LQMNSLRAED       TAVYYCAKIL       100
                           GAGRGWYFDY WGKGTTVTVS SASTKGPSVF                  PLAPSSKSTS       GGTAALGCLV       150
                           KDYFPEPVTV SWNSGALTSG VHTFPAVLQS                  SGLYSLSSVV       TVPSSSLGTQ       200
                           TYICNVNHKP SNTKVDKKVE PKSCDKTHTC                  PPCPAPELLG       GPSVFLFPPK       250
                           PKDTLMISRT PEVTCVVVDV SHEDPEVKFN                  WYVDGVEVHN       AKTKPREEQY       300
                           NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK                  ALPAPIEKTI       SKAKGQPREP       350
                           QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD                  IAVEWESNGQ       PENNYKTTPP       400
                           VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS                  VMHEALHNHY       TQKSLSLSPG       450
                           K                                                                                   451

                           Light chain / Chaîne légère / Cadena ligera
                           SELTQDPAVS VALGQTVRIT CSGDSLRSYY                  ASWYQQKPGQ       APVLVIYGAN 50
                           NRPSGIPDRF SGSSSGNTAS LTITGAQAED                  EADYYCNSAD       SSGNHVVFGG 100
                           GTKLTVLGQP KAAPSVTLFP PSSEELQANK                  ATLVCLISDF       YPGAVTVAWK 150
                           ADSSPVKAGV ETTTPSKQSN NKYAASSYLS                  LTPEQWKSHK       SYSCQVTHEG 200
                           STVEKTVAPT ECS                                                                213

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96        148-204       265-325  371-429
                                     22''-96'' 148''-204'' 265''-325'' 371''-429''
                           Intra-L 21'-86'      135'-194'
                                    21'''-86''' 135'''-194'''
                           Inter-H-L 224-212' 224''-212'''
                           Inter-H-H 230-230'' 233-233''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           301, 301''



 dulaglutidum #
 dulaglutide               glucagon-like peptide-1-immunoglobulin G4 fusion protein,
                           [2-glycyl,16-L-glutamyl,30-glycyl][human glucagon-like peptide 1-(7-
                           37)-peptide] {(8-A>G,22-G>E,36-R>G)-GLP-1(7-37)} fusion protein
                           with tris(tetraglycyl-L-seryl)-L-alanine (linker) fusion protein with des-
                           276-lysine-[57-L-proline,63-L-alanine,64-L-alanine]human
                           immunoglobulin G4 Fc region {(10-S>P)-H-(4-F>A,5-L>A)-CH2-(107-
                           K>-)-CH3 of IGHG4*01}, dimer (55-55':58-58')-bisdisulfide

 dulaglutide               protéine de fusion entre le peptide 1 semblable au glucagon et
                           l'immunoglobuline G4,
                           [2-glycyl,16-L-glutamyl,30-glycyl][peptide 1 semblable au glucagon
                           humain-(7-37)-peptide] {(8-A>G,22-G>E,36-R>G)GLP-1(7-37)}
                           protéine de fusion avec le tris(tétraglycyl-L-séryl)-L-alanine (lien)
                           protéine de fusion avec la dès-276-lysine-[57-L-proline,63-L-
                           alanine,64-L-alanine]région Fc de l'immunoglobuline G4 humaine
                           {(10-S>P)H-(4-F>A,5-L>A)CH2-(107-K>-)CH3 du IGHG4*01}, (55-
                           55':58-58')-bisdisulfure du dimère




56
WHO Drug Information, Vol. 25, No. 1, 2011                                                              Recommended INN: List 65




 dulaglutida                                 proteína de fusión entre el péptido similar al glucagón 1 y la
                                             inmunoglobulina G4,
                                             [2-glicil,16-L-glutamil,30-glicil][péptido similar al glucagón humano 1-
                                             (7-37)-péptido] {(8-A>G,22-G>E,36-R>G)GLP-1(7-37)} proteína de
                                             fusión con el tris(tetraglicil-L-seril)-L-alanina (vínculo) proteína de
                                             fusión con la des-276-lisina-[57-L-prolina, 63-L-alanina,64-L-
                                             alanina]región Fc de la inmunoglobulina G4 humana {(10-S>P)H-(4-
                                             F>A,5-L>A)CH2-(107-K>-)CH3 del IGHG4*01}, (55-55':58-58')-
                                             bisdisulfuro del dímero

                                             C2646H4044N704O836S18

                                             Monomer / Monomère / Monomero
                                             HGEGTFTSDV SSYLEEQAAK EFIAWLVKGG                       GGGGGSGGGG        SGGGGSAESK         50
                                             YGPPCPPCPA PEAAGGPSVF LFPPKPKDTL                       MISRTPEVTC        VVVDVSQEDP         100
                                             EVQFNWYVDG VEVHNAKTKP REEQFNSTYR                       VVSVLTVLHQ        DWLNGKEYKC         150
                                             KVSNKGLPSS IEKTISKAKG QPREPQVYTL                       PPSQEEMTKN        QVSLTCLVKG         200
                                             FYPSDIAVEW ESNGQPENNY KTTPPVLDSD                       GSFFLYSRLT        VDKSRWQEGN         250
                                             VFSCSVMHEA LHNHYTQKSL SLSLG                                                                 275

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             55-55' 58-58' 90-150 90'-150' 196-254 196'-254'


 eliglustatum
 eliglustat                                  N-{(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-
                                             3-(pyrrolidin-1-yl)propan-2-yl}octanamide

 éliglustat                                  N-{(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-
                                             3-(pyrrolidin-1-yl)propan-2-yl}octanamide

 eliglustat                                  N-{(1R,2R)-1-(2,3-dihidro-1,4-benzodioxin-6-il)-1-hidroxi-3-(pirrolidin-
                                             1-il)propan-2-il}octanamida

                                             C23H36N2O4



                                                                                        N                  O
                                                                              O             H

                                             H3C                                  N                        O
                                                                                  H
                                                                                        H OH

 elpamotidum
 elpamotide                                  L-arginyl-L-phenylalanyl-L-valyl-L-prolyl-L-α-aspartylglycyl-
                                             L-asparaginyl-L-arginyl-L-isoleucine
                                             human soluble (Vascular Endothelial Growth Factor Receptor)
                                             VEGFR2-(169-177)-peptide

 elpamotide                                  L-arginyl-L-phénylalanyl-L-valyl-L-prolyl-L-α-aspartylglycyl-
                                             L-asparaginyl-L-arginyl-L-isoleucine
                                             (Récepteur du Facteur de Croissance de l'Endothélium Vasculaire)
                                             RFCEV2 soluble humain-(169-177)-peptide

 elpamotida                                  L-arginil-L-fenilalanil-L-valil-L-prolil-L-α-aspartilglicil-L-asparaginil-
                                             L-arginil-L-isoleucina
                                             (receptor del factor de crecimiento endotelial vascular) RFCEV2
                                             soluble humano-(169-177)-péptido

                                             C47H76N16O13

                                             H Arg       Phe     Val    Pro       Asp       Gly   Asn    Arg    Ile OH
                                                                                                                 9




                                                                                                                                               57
Recommended INN: List 65                                    WHO Drug Information, Vol. 25, No. 1, 2011




 ensituximabum #
 ensituximab               immunoglobulin G1-kappa, anti-[Homo sapiens MUC5AC (mucin
                           5AC, mucin 5 subtypes A and C tracheobronchial/gastric)], chimeric
                           monoclonal antibody;
                           gamma1 heavy chain (1-443) [Mus musculus VH (IGHV2-3*01 -
                           (IGHD)-IGHJ4*01) [8.7.7] (1-113) -Homo sapiens IGHG1*01 CH1
                           L85.3>P, CH3 T81>M (114-443)], (216-213')-disulfide with kappa
                           light chain (1'-213') [Mus musculus V-KAPPA (IGKV4-70*01 -
                           IGKJ1*01) [5.3.9] (1'-106') -Homo sapiens IGKC*01 (107'-213')];
                           (222-222'':225-225'')-bisdisulfide dimer

 ensituximab               immunoglobuline G1-kappa, anti-[Homo sapiens MUC5AC (mucine
                           5AC, mucine 5 de sous-types A et C trachéo-bronchique/gastrique)],
                           anticorps monoclonal chimérique;
                           chaîne lourde gamma1 (1-443) [Mus musculus VH (IGHV2-3*01 -
                           (IGHD)-IGHJ4*01) [8.7.7] (1-113) -Homo sapiens IGHG1*01 CH1
                           L85.3>P, CH3 T81>M (114-443)], (216-213')-disulfure avec la
                           chaîne légère kappa (1'-213') [Mus musculus V-KAPPA (IGKV4-
                           70*01 -IGKJ1*01) [5.3.9] (1'-106') -Homo sapiens IGKC*01 (107'-
                           213')]; dimère (222-222'':225-225'')-bisdisulfure

 ensituximab               inmunoglobulina G1-kappa, anti-[Homo sapiens MUC5AC (mucina
                           5AC, mucina 5 de subtipos A y C traqueo-bronquial/gástrico],
                           anticuerpo monoclonal quimérico;
                           cadena pesada gamma1 (1-443) [Mus musculus VH (IGHV2-3*01 -
                           (IGHD)-IGHJ4*01) [8.7.7] (1-113) -Homo sapiens IGHG1*01 CH1
                           L85.3>P, CH3 T81>M (114-443)], (216-213')-disulfuro con la cadena
                           ligera kappa (1'-213') [Mus musculus V-KAPPA (IGKV4-70*01 -
                           IGKJ1*01) [5.3.9] (1'-106') -Homo sapiens IGKC*01 (107'-213')];
                           dímero (222-222'':225-225'')-bisdisulfuro


                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLKESGPD LVAPSQSLSI TCTVSGFSLS                  KFGVNWVRQP       PGKGLEWLGV        50
                           IWGDGSTSYN SGLISRLSIS KENSKSQVFL                  KLNSLQADDT       ATYYCVKPGG       100
                           DYWGHGTSVT VSSASTKGPS VFPLAPSSKS                  TSGGTAALGC       LVKDYFPEPV       150
                           TVSWNSGALT SGVHTFPAVL QSSGPYSLSS                  VVTVPSSSLG       TQTYICNVNH       200
                           KPSNTKVDKK VEPKSCDKTH TCPPCPAPEL                  LGGPSVFLFP       PKPKDTLMIS       250
                           RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV                  HNAKTKPREE       QYNSTYRVVS       300
                           VLTVLHQDWL NGKEYKCKVS NKALPAPIEK                  TISKAKGQPR       EPQVYTLPPS       350
                           RDELTKNQVS LTCLVKGFYP SDIAVEWESN                  GQPENNYKTM       PPVLDSDGSF       400
                           FLYSKLTVDK SRWQQGNVFS CSVMHEALHN                  HYTQKSLSLS       PGK              443

                           Light chain / Chaîne légère / Cadena ligera
                           QVVLTQSPVI MSASPGEKVT MTCSASSSIS                  YMYWYQQKPG       TSPKRWIYDT 50
                           SKLASGVPAR FSGSGSGTSY SLTISNMEAG                  DAATYYCHQR       DSYPWTFGGG 100
                           TNLEIKRTVA APSVFIFPPS DEQLKSGTAS                  VVCLLNNFYP       REAKVQWKVD 150
                           NALQSGNSQE SVTEQDSKDS TYSLSSTLTL                  SKADYEKHKV       YACEVTHQGL 200
                           SSPVTKSFNR GEC                                                                213

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-95 140-196            257-317    363-421
                                    22''-95'' 140''-196'' 257''-317'' 363''-421''
                           Intra-L 23'-87' 133'-193'
                                    23'''-87''' 133'''-193'''
                           Inter-H-L 216-213' 216''-213'''
                           Inter-H-H 222-222'' 225-225''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           293, 293''




58
WHO Drug Information, Vol. 25, No. 1, 2011                                             Recommended INN: List 65




 eteplirsenum
 eteplirsen                                  all-P-ambo-5'-{P-[4-({2-[2-(2-
                                             hydroxyethoxy)ethoxy]ethoxy}carbonyl)piperazin-1-yl]-N,N-
                                             dimethylphosphonamidate}-P,2',3'-trideoxy-P-dimethylamino-2',3'-
                                             imino-2',3'-secocytidylyl-(2'a→5')-P,3'-dideoxy-P-dimethylamino-2',3'-
                                             imino-2',3'-secothymidylyl-(2'a→5')-P,2',3'-trideoxy-P-dimethylamino-
                                             2',3'-imino-2',3'-secocytidylyl-(2'a→5')-P,2',3'-trideoxy-P-
                                             dimethylamino-2',3'-imino-2',3'-secocytidylyl-(2'a→5')-P,2',3'-
                                             trideoxy-P-dimethylamino-2',3'-imino-2',3'-secoadenylyl-(2'a→5')-
                                             P,2',3'-trideoxy-P-dimethylamino-2',3'-imino-2',3'-secoadenylyl-
                                             (2'a→5')-P,2',3'-trideoxy-P-dimethylamino-2',3'-imino-2',3'-
                                             secocytidylyl-(2'a→5')-P,2',3'-trideoxy-P-dimethylamino-2',3'-imino-
                                             2',3'-secoadenylyl-(2'a→5')-P,3'-dideoxy-P-dimethylamino-2',3'-
                                             imino-2',3'-secothymidylyl-(2'a→5')-P,2',3'-trideoxy-P-dimethylamino-
                                             2',3'-imino-2',3'-secocytidylyl-(2'a→5')-P,2',3'-trideoxy-P-
                                             dimethylamino-2',3'-imino-2',3'-secoadenylyl-(2'a→5')-P,2',3'-
                                             trideoxy-P-dimethylamino-2',3'-imino-2',3'-secoadenylyl-(2'a→5')-
                                             P,2',3'-trideoxy-P-dimethylamino-2',3'-imino-2',3'-secoguanylyl-
                                             (2'a→5')-P,2',3'-trideoxy-P-dimethylamino-2',3'-imino-2',3'-
                                             secoguanylyl-(2'a→5')-P,2',3'-trideoxy-P-dimethylamino-2',3'-imino-
                                             2',3'-secoadenylyl-(2'a→5')-P,2',3'-trideoxy-P-dimethylamino-2',3'-
                                             imino-2',3'-secoadenylyl-(2'a→5')-P,2',3'-trideoxy-P-dimethylamino-
                                             2',3'-imino-2',3'-secoguanylyl-(2'a→5')-P,2',3'-trideoxy-P-
                                             dimethylamino-2',3'-imino-2',3'-secoadenylyl-(2'a→5')-P,3'-dideoxy-
                                             P-dimethylamino-2',3'-imino-2',3'-secothymidylyl-(2'a→5')-P,2',3'-
                                             trideoxy-P-dimethylamino-2',3'-imino-2',3'-secoguanylyl-(2'a→5')-
                                             P,2',3'-trideoxy-P-dimethylamino-2',3'-imino-2',3'-secoguanylyl-
                                             (2'a→5')-P,2',3'-trideoxy-P-dimethylamino-2',3'-imino-2',3'-
                                             secocytidylyl-(2'a→5')-P,2',3'-trideoxy-P-dimethylamino-2',3'-imino-
                                             2',3'-secoadenylyl-(2'a→5')-P,3'-dideoxy-P-dimethylamino-2',3'-
                                             imino-2',3'-secothymidylyl-(2'a→5')-P,3'-dideoxy-P-dimethylamino-
                                             2',3'-imino-2',3'-secothymidylyl-(2'a→5')-P,3'-dideoxy-P-
                                             dimethylamino-2',3'-imino-2',3'-secothymidylyl-(2'a→5')-P,2',3'-
                                             trideoxy-P-dimethylamino-2',3'-imino-2',3'-secocytidylyl-(2'a→5')-
                                             P,3'-dideoxy-P-dimethylamino-2',3'-imino-2',3'-secothymidylyl-
                                             (2'a→5')-P,2',3'-trideoxy-P-dimethylamino-2',3'-imino-2',3'-
                                             secoadenylyl-(2'a→5')-2',3'-dideoxy-2',3'-imino-2',3'-secoguanosine




                                                                                                                  59
Recommended INN: List 65                            WHO Drug Information, Vol. 25, No. 1, 2011




 étéplirsen                tout-P-ambo-5'-{P-[4-({2-[2-(2-
                           hydroxyéthoxy)éthoxy]éthoxy}carbonyl)pipérazin-1-yl]-N,N-
                           diméthylphosphonamidate}-P,2',3'-tridésoxy-P-diméthylamino-2',3'-
                           imino-2',3'-sécocytidylyl-(2'a→5')-P,3'-didésoxy-P-diméthylamino-
                           2',3'-imino-2',3'-sécothymidylyl-(2'a→5')-P,2',3'-tridésoxy-P-
                           diméthylamino-2',3'-imino-2',3'-sécocytidylyl-(2'a→5')-P,2',3'-
                           tridésoxy-P-diméthylamino-2',3'-imino-2',3'-sécocytidylyl-(2'a→5')-
                           P,2',3'-tridésoxy-P-diméthylamino-2',3'-imino-2',3'-sécoadénylyl-
                           (2'a→5')-P,2',3'-tridésoxy-P-diméthylamino-2',3'-imino-2',3'-
                           sécoadénylyl-(2'a→5')-P,2',3'-tridésoxy-P-diméthylamino-2',3'-imino-
                           2',3'-sécocytidylyl-(2'a→5')-P,2',3'-tridésoxy-P-diméthylamino-2',3'-
                           imino-2',3'-sécoadénylyl-(2'a→5')-P,3'-didésoxy-P-diméthylamino-
                           2',3'-imino-2',3'-sécothymidylyl-(2'a→5')-P,2',3'-tridésoxy-P-
                           diméthylamino-2',3'-imino-2',3'-sécocytidylyl-(2'a→5')-P,2',3'-
                           tridésoxy-P-diméthylamino-2',3'-imino-2',3'-sécoadénylyl-(2'a→5')-
                           P,2',3'-tridésoxy-P-diméthylamino-2',3'-imino-2',3'-sécoadénylyl-
                           (2'a→5')-P,2',3'-tridésoxy-P-diméthylamino-2',3'-imino-2',3'-
                           sécoguanylyl-(2'a→5')-P,2',3'-tridésoxy-P-diméthylamino-2',3'-imino-
                           2',3'-sécoguanylyl-(2'a→5')-P,2',3'-tridésoxy-P-diméthylamino-2',3'-
                           imino-2',3'-sécoadénylyl-(2'a→5')-P,2',3'-tridésoxy-P-diméthylamino-
                           2',3'-imino-2',3'-sécoadénylyl-(2'a→5')-P,2',3'-tridésoxy-P-
                           diméthylamino-2',3'-imino-2',3'-sécoguanylyl-(2'a→5')-P,2',3'-
                           tridésoxy-P-diméthylamino-2',3'-imino-2',3'-sécoadénylyl-(2'a→5')-
                           P,3'-didésoxy-P-diméthylamino-2',3'-imino-2',3'-sécothymidylyl-
                           (2'a→5')-P,2',3'-tridésoxy-P-diméthylamino-2',3'-imino-2',3'-
                           sécoguanylyl-(2'a→5')-P,2',3'-tridéoxy-P-diméthylamino-2',3'-imino-
                           2',3'-sécoguanylyl-(2'a→5')-P,2',3'-tridéoxy-P-diméthylamino-2',3'-
                           imino-2',3'-sécocytidylyl-(2'a→5')-P,2',3'-tridésoxy-P-diméthylamino-
                           2',3'-imino-2',3'-sécoadénylyl-(2'a→5')-P,3'-didésoxy-P-
                           diméthylamino-2',3'-imino-2',3'-sécothymidylyl-(2'a→5')-P,3'-
                           didésoxy-P-diméthylamino-2',3'-imino-2',3'-sécothymidylyl-(2'a→5')-
                           P,3'-didésoxy-P-diméthylamino-2',3'-imino-2',3'-sécothymidylyl-
                           (2'a→5')-P,2',3'-tridésoxy-P-diméthylamino-2',3'-imino-2',3'-
                           sécocytidylyl-(2'a→5')-P,3'-didésoxy-P-diméthylamino-2',3'-imino-
                           2',3'-sécothymidylyl-(2'a→5')-P,2',3'-tridésoxy-P-diméthylamino-2',3'-
                           imino-2',3'-sécoadenylyl-(2'a→5')-2',3'-didésoxy-2',3'-imino-2',3'-
                           sécoguanosine




60
WHO Drug Information, Vol. 25, No. 1, 2011                                                            Recommended INN: List 65




 eteplirsén                                  todo-P-ambo-5'-{P-[4-({2-[2-(2-
                                             hidroxietoxi)etoxi]etoxi}carbonl)piperazin-1-il]-N,N-
                                             dimetilfosfonamidato}-P,2',3'-tridesoxi-P-dimetilamino-2',3'-imino-
                                             2',3'-secocitidilil-(2'a→5')-P,3'-didesoxi-P-dimetilamino-2',3'-imino-
                                             2',3'-secotimidilil-(2'a→5')-P,2',3'-tridesoxi-P-dimetilamino-2',3'-imino-
                                             2',3'-secocitidilil-(2'a→5')-P,2',3'-tridesoxi-P-dimetilamino-2',3'-imino-
                                             2',3'-secocitidilil-(2'a→5')-P,2',3'-tridesoxi-P-dimetilamino-2',3'-imino-
                                             2',3'-secoadenilil-(2'a→5')-P,2',3'-tridesoxi-P-dimetilamino-2',3'-
                                             imino-2',3'-secoadenilil-(2'a→5')-P,2',3'-tridesoxi-P-dimetilamino-
                                             2',3'-imino-2',3'-secocitidilil-(2'a→5')-P,2',3'-tridesoxi-P-dimetilamino-
                                             2',3'-imino-2',3'-secoadenilil-(2'a→5')-P,3'-didesoxi-P-dimetilamino-
                                             2',3'-imino-2',3'-secotimidilil-(2'a→5')-P,2',3'-tridesoxi-P-dimetilamino-
                                             2',3'-imino-2',3'-secocitidilil-(2'a→5')-P,2',3'-tridesoxi-P-dimetilamino-
                                             2',3'-imino-2',3'-secoadenilil-(2'a→5')-P,2',3'-tridesoxi-P-
                                             dimetilamino-2',3'-imino-2',3'-secoadenil-(2'a→5')-P,2',3'-tridesoxi-P-
                                             dimetilamino-2',3'-imino-2',3'-secoguanilil-(2'a→5')-P,2',3'-tridesoxi-
                                             P-dimetilamino-2',3'-imino-2',3'-secoguanilil-(2'a→5')-P,2',3'-
                                             tridesoxi-P-dimetilamino-2',3'-imino-2',3'-secoadenilil-(2'a→5')-
                                             P,2',3'-tridesoxi-P-dimetilamino-2',3'-imino-2',3'-secoadenilil-
                                             (2'a→5')-P,2',3'-tridesoxi-P-dimetilamino-2',3'-imino-2',3'-
                                             secoguanilil-(2'a→5')-P,2',3'-tridesoxi-P-dimetilamino-2',3'-imino-
                                             2',3'-secoadenilil-(2'a→5')-P,3'-didesoxi-P-dimetilamino-2',3'-imino-
                                             2',3'-secotimidilil-(2'a→5')-P,2',3'-tridesoxi-P-dimetilamino-2',3'-imino-
                                             2',3'-secoguanilil-(2'a→5')-P,2',3'-tridesoxi-P-dimetilamino-2',3'-
                                             imino-2',3'-secoguanilil-(2'a→5')-P,2',3'-tridesoxi-P-dimetilamino-
                                             2',3'-imino-2',3'-secocitidilil-(2'a→5')-P,2',3'-tridesoxi-P-dimetilamino-
                                             2',3'-imino-2',3'-secoadenill-(2'a→5')-P,3'-didesoxi-P-dimetilamino-
                                             2',3'-imino-2',3'-secotimidilil-(2'a→5')-P,3'-didesoxi-P-dimetilamino-
                                             2',3'-imino-2',3'-secotimidilil-(2'a→5')-P,3'-didesoxi-P-dimetilamino-
                                             2',3'-imino-2',3'-secotimidilil-(2'a→5')-P,2',3'-tridesoxi-P-dimetilamino-
                                             2',3'-imino-2',3'-secocitidilil-(2'a→5')-P,3'-didesoxi-P-dimetilamino-
                                             2',3'-imino-2',3'-secotimidilil-(2'a→5')-P,2',3'-tridesoxi-P-dimetilamino-
                                             2',3'-imino-2',3'-secoadenilil-(2'a→5')-2',3'-didesoxi-2',3'-imino-2',3'-
                                             secoguanosina

                                             C364H569N177O122P30

                                                             O                             B(n)                        B(30)

                                                       O         N                       O 1'                      O
                                                                                            2'a
                                               HO                       N       O                 N       O              NH
                                                             3              P                         P
                                                                                    5'
                                                                     H3 C N O             H3 C N O
                                                                           CH3                  CH3
                                                n = 1 - 29                                                    29

                                                                       B(1-30):
                                             C-T-C-C-A-A-C-A-T-C-A-A-G-G-A-A-G-A-T-G-G-C-A-T-T-T-C-T-A-G




                                                                                                                               61
Recommended INN: List 65                                      WHO Drug Information, Vol. 25, No. 1, 2011


 fasitibanti chloridum
 fasitibant chloride       (4S)-4-amino-5-{4-[4-(2,4-dichloro-3-{[(2,4-dimethylquinolin-
                           8-yl)oxy]methyl}benzenesulfonamido)oxane-4-carbonyl]piperazin-
                           1-yl}-N,N,N-trimethyl-5-oxopentan-1-aminium chloride

 chlorure de fasitibant    chlorure de (4S)-4-amino-5-{4-[4-(2,4-dichloro-3-{[(2,4-
                           diméthylquinoléin-8-yl)oxy]méthyl}benzènesulfonamido)oxane-
                           4-carbonyl]pipérazin-1-yl}-N,N,N-triméthyl-5-oxopentan-1-aminium

 cloruro de fasitibant     cloruro de (4S)-4-amino-5-{4-[4-(2,4-dicloro-3-{[(2,4-dimetilquinolein-
                           8-il)oxi]metil}bencenosulfonamido)oxano-4-carbonil]piperazin-1-il}-
                           N,N,N-trimetil-5-oxopentan-1-aminio

                           C36H49Cl3N6O6S

                                              Cl
                                                                                      O
                                                                          H                                   Cl
                                          O                               N
                                                                  S                       N         H   NH2   CH3
                                                     Cl       O O                               N             N    CH3
                                          N
                                                                                  O                               CH3
                                                                                                    O
                           H3 C                CH3



 fedovapagonum
                                  2   2                   1
 fedovapagon               (2S)-N ,N -dimethyl-N -{[2-methyl-4-(2,3,4,5-tetrahydro-
                           1H-1-benzazepine-1-carbonyl)phenyl]methyl}pyrrolidine-
                           1,2-dicarboxamide
                                  2   2                   1
 fédovapagon               (2S)-N ,N -diméthyl-N -{[2-méthyl-4-(2,3,4,5-tétrahydro-
                           1H-1-benzazépine-1-carbonyl)phényl]méthyl}pyrrolidine-
                           1,2-dicarboxamide
                                  2   2              1
 fedovapagón               (2S)-N ,N -dimetil-N -{[2-metil-4-(2,3,4,5-tetrahidro-
                           1H-1-benzazepina-1-carbonil)fenil]metil}pirrolidina-
                           1,2-dicarboxamida

                           C27H34N4O3

                                                                                      O
                                                                      O                       CH3
                                                                                  H
                                                                                          N
                                                              N               N               CH3
                                                              H
                                  N
                                                         CH3
                                      O


                    18
 florbetapirum ( F)
              18                                         18
 florbetapir ( F)          4-[(1E)-2-(6-{2-[2-(2-[ F]fluoroethoxy)ethoxy]ethoxy}pyridine-
                           3-yl)ethen-1-yl]-N-methylaniline
             18                                          18
 florbétapir ( F)          4-[(1E)-2-(6-{2-[2-(2-[ F]fluoroéthoxy)éthoxy]éthoxy}pyridin-
                           3-yl)éthén-1-yl]-N-méthylaniline
             18                                          18
 florbetapir ( F)          4-[(1E)-2-(6-{2-[2-(2-[ F]fluoroetoxi)etoxi]etoxi}piridin-3-il)eten-1-il]-
                           N-metilanilina




62
WHO Drug Information, Vol. 25, No. 1, 2011                                                                     Recommended INN: List 65


                                                          18
                                             C20H25 FN2O3

                                                      H
                                                      N
                                             H3 C



                                                                                                               O                       [18F]
                                                                                           N         O                     O

                   18
 fluciclatidum ( F)
               18                             6                         18
 fluciclatide ( F)                           N -[(28E)-29-(4-[ F]fluorophenyl)-5,25-dioxo-3,9,12,15,18,21,27-
                                                                                             2
                                             heptaoxa-6,24,28-triazanonacos-28-enoyl]-N -(sulfanylacetyl)-
                                             L-lysyl-L-cysteinyl-L-arginylglycyl-L-α-aspartyl-L-cysteinyl-
                                             L-phenylalanyl-N-(17-amino-13,17-dioxo-3,6,9,15-tetraoxa-
                                             12-azaheptadecyl)-L-cysteinamide cyclic (2→6)-disulfide cyclic
                                             (1→8)-thioether
             18                                                                                                                    6
 fluciclatide ( F)                           (2→6)-disulfure cyclique et (1→8)-thioéther cyclique du N -[(28E)-
                                                    18
                                             29-(4-[ F]fluorophényl)-5,25-dioxo-3,9,12,15,18,21,27-heptaoxa-
                                                                                 2
                                             6,24,28-triazanonacos-28-énoyl]-N -(2-sulfanylacétyl)-L-lysyl-
                                             L-cystéinyl-L-arginylglycyl-L-α-aspartyl-L-cystéinyl-L-phénylalanyl-
                                             1-N-(17-amino-13,17-dioxo-3,6,9,15-tétraoxa-12-azaheptadécyl)-
                                             L-cystéinamide

             18                                                                                                            6
 fluciclatida ( F)                           (2→6)-disulfuro cíclico y (1→8)-tioéter cíclico del N -[(28E)-29-(4-
                                              18
                                             [ F]fluorofenil)-5,25-dioxo-3,9,12,15,18,21,27-heptaoxa-6,24,28-
                                                                           2
                                             triazanonacos-28-enoil]-N -(2-sulfanilacetil)-L-lisil-L-cisteinil-
                                             L-arginilglicil-L-α-aspartil-L-cisteinil-L-fenilalanil-1-N-(17-amino-
                                             13,17-dioxo-3,6,9,15-tetraoxa-12-azaheptadecil)-L-cisteinamida
                                                           18
                                             C75H115 FN18O27S3

                                                                       O                   O
                                                                                 O                         O
                                                                H2N                              N                     O
                                                                                                 H
                                                                                                                               O
                                                                                      S                                H

                                                       Lys      Cys        Arg   Gly           Asp   Cys   Phe     N           N
                                             O        N6
                                                                                                                   H           H
                                                                            O                                              O
                                                                 O                               O                     O
                                                  O                              N                         O
                                                                                 H
                                                                                                 O                     O
                                                                                      O                        O
                                                                                 N                   N
                                                                                                     H
                                                     18
                                                  [ F]

                     18
 fluciclovinum ( F)
               18                                                          18
 fluciclovine ( F)                           (1r,3r)-1-amino-3[ F]fluorocyclobutane-1-carboxylic acid
              18                                                                     18
 fluciclovine ( F)                           acide trans-1-amino-3-[ F]fluorocyclobutane-1-carboxylique
              18                                                                      18
 fluciclovina ( F)                           ácido (1r,3r)-1-amino-3-[ F]fluorociclobutano-1-carboxílico
                                                     18
                                             C5H8 FNO2

                                                  H                   NH2
                                             [18F]                    CO2H




                                                                                                                                               63
Recommended INN: List 65                            WHO Drug Information, Vol. 25, No. 1, 2011




                    18
 flurpiridazum ( F)
              18
 flurpiridaz ( F)          2-tert-butyl-4-chloro-5-({4-[(2-
                            18
                           [ F]fluoroethoxy)methyl]phenyl}methoxy)pyridazin-3(2H)-one
             18
 flurpiridaz ( F)          2-tert-butyl-4-chloro-5-({4-[(2-
                            18
                           [ F]fluoroéthoxy)méthyl]phényl}méthoxy)pyridazin-3(2H)-one
             18
 flurpiridaz ( F)          2-terc-butil-4-cloro-5-({4-[(2-
                            18
                           [ F]fluoroetoxi)metil]fenil}metoxi)piridazin-3(2H)-ona
                                   18
                           C18H22Cl FN2O3

                            H3 C   CH3 O
                                            Cl
                           H3C      N
                                    N
                                            O
                                                              O
                                                                        [18F]



 foralumabum #
 foralumab                 immunoglobulin G1-kappa, anti-[Homo sapiens CD3E (CD3
                           epsilon)], Homo sapiens monoclonal antibody;
                           gamma1 heavy chain (1-448) [Homo sapiens VH (IGHV3-33*01
                           (95.90%) -(IGHD)-IGHJ2*01) [8.8.11] (1-118) -IGHG1*03 CH2
                           L1.3(235)>A, L1.2(236)>E (119-448)], (221-215')-disulfide with
                           kappa light chain (1'-215') [Homo sapiens V-KAPPA (IGKV3-11*01
                           (100.00%) -IGKJ4*01) [6.3.10] (1'-108') -IGKC*01 (109'-215')]; (227-
                           227'':230-230'')-bisdisulfide dimer

 foralumab                 immunoglobuline G1 -kappa, anti-[Homo sapiens CD3E (CD3
                           epsilon)], Homo sapiens anticorps monoclonal;
                           chaîne lourde gamma1 (1-448) [Homo sapiens (IGHV3-33*01
                           (95.90%) -(IGHD)-IGHJ2*01) [8.8.11] (1-118) -IGHG1*03 CH2
                           L1.3(235)>A, L1.2(236)>E (119-448)], (221-215')-disulfure avec la
                           chaîne légère kappa (1'-215') [Homo sapiens V-KAPPA (IGKV3-
                           11*01 (100.00%) -IGKJ4*01) [6.3.10] (1'-108') -IGKC*01 (109'-215')];
                           dimère (227-227'':230-230'')-bisdisulfure

 foralumab                 inmunoglobulina G1-kappa, anti-[Homo sapiens CD3E (CD3
                           epsilon)], anticuerpo monoclonal de Homo sapiens;
                           cadena pesada gamma1 (1-448) [Homo sapiens (IGHV3-33*01
                           (95.90%) -(IGHD)-IGHJ2*01) [8.8.11] (1-118) -IGHG1*03 CH2
                           L1.3(235)>A, L1.2(236)>E (119-448)], (221-215')-disulfuro con la
                           cadena ligera kappa (1'-215') [Homo sapiens V-KAPPA (IGKV3-
                           11*01 (100.00%) -IGKJ4*01) [6.3.10] (1'-108') -IGKC*01 (109'-215')];
                           dímero (227-227'':230-230'')-bisdisulfuro




64
WHO Drug Information, Vol. 25, No. 1, 2011                                                           Recommended INN: List 65




                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             QVQLVESGGG VVQPGRSLRL SCAASGFKFS                  GYGMHWVRQA       PGKGLEWVAV        50
                                             IWYDGSKKYY VDSVKGRFTI SRDNSKNTLY                  LQMNSLRAED       TAVYYCARQM       100
                                             GYWHFDLWGR GTLVTVSSAS TKGPSVFPLA                  PSSKSTSGGT       AALGCLVKDY       150
                                             FPEPVTVSWN SGALTSGVHT FPAVLQSSGL                  YSLSSVVTVP       SSSLGTQTYI       200
                                             CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC                  PAPEAEGGPS       VFLFPPKPKD       250
                                             TLMISRTPEV TCVVVDVSHE DPEVKFNWYV                  DGVEVHNAKT       KPREEQYNST       300
                                             YRVVSVLTVL HQDWLNGKEY KCKVSNKALP                  APIEKTISKA       KGQPREPQVY       350
                                             TLPPSREEMT KNQVSLTCLV KGFYPSDIAV                  EWESNGQPEN       NYKTTPPVLD       400
                                             SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH                  EALHNHYTQK       SLSLSPGK         448

                                             Light chain / Chaîne légère / Cadena ligera
                                             EIVLTQSPAT LSLSPGERAT LSCRASQSVS                  SYLAWYQQKP       GQAPRLLIYD 50
                                             ASNRATGIPA RFSGSGSGTD FTLTISSLEP                  EDFAVYYCQQ       RSNWPPLTFG 100
                                             GGTKVEIKRT VAAPSVFIFP PSDEQLKSGT                  ASVVCLLNNF       YPREAKVQWK 150
                                             VDNALQSGNS QESVTEQDSK DSTYSLSSTL                  TLSKADYEKH       KVYACEVTHQ 200
                                             GLSSPVTKSF NRGEC                                                              215

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H 22-96        145-201       262-322   368-426
                                                      22''-96'' 145''-201'' 262''-322'' 368''-426''
                                             Intra-L 23'-88'       135'-195'
                                                      23'''-88''' 135'''-195'''
                                             Inter-H-L 221-215' 221''-215'''
                                             Inter-H-H 227-227'' 230-230''

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             298, 298''




 fosdevirinum
 fosdevirine                                 methyl (R)-(2-carbamoyl-5-chloro-1H-indol-3-yl){3-[(1E)-2-
                                             cyanoethen-1-yl]-5-methylphenyl}phosphinate

 fosdévirine                                 (R)-(2-carbamoyl-5-chloro-1H-indol-3-yl){3-[(1E)-2-cyanoéthén-1-yl]-
                                             5-méthylphényl}phosphinate de méthyle

 fosdevirina                                 (R)-(2-carbamoil-5-cloro-1H-indol-3-il){3-[(1E)-2-cianoeten-1-il]-
                                             5-metilfenil}fosfinato de metilo

                                             C20H17ClN3O3P

                                                    NH2
                                             O
                                                      O O CH3
                                                        P                         CN
                                              HN


                                                                  CH3
                                                           Cl




 ganitumabum #
 ganitumab                                   immunoglobulin G1-kappa, anti-[Homo sapiens IGF1R (insulin-like
                                             growth factor 1 receptor, IGF1-R, IGF-1R, CD221)], Homo sapiens
                                             monoclonal antibody;
                                             gamma1 heavy chain (1-449) [Homo sapiens VH (IGHV4-4*02
                                             (100.00%) -(IGHD)-IGHJ3*02) [9.7.12] (1-119) -IGHG1*01 (120-
                                             449)], (222-219')-disulfide with kappa light chain (1'-219') [Homo
                                             sapiens V-KAPPA (IGKV2-28*01 (95.00%) -IGKJ1*01) [11.3.9] (1'-
                                             112') -IGKC*01 (113'-219')]; (228-228'':231-231'')-bisdisulfide dimer




                                                                                                                                         65
Recommended INN: List 65                                    WHO Drug Information, Vol. 25, No. 1, 2011


 ganitumab                 immunoglobuline G1-kappa, anti-[Homo sapiens IGF1R (récepteur
                           du facteur de croissance 1 analogue à l'insuline, IGF1-R, IGF-1R,
                           CD221)], Homo sapiens anticorps monoclonal;
                           chaîne lourde gamma1 (1-449) [Homo sapiens VH (IGHV4-4*02
                           (100.00%) -(IGHD)-IGHJ3*02) [9.7.12] (1-119) -IGHG1*01 (120-
                           449)], (222-219')-disulfure avec la chaîne légère kappa (1'-219')
                           [Homo sapiens V-KAPPA (IGKV2-28*01 (95.00%) -IGKJ1*01)
                           [11.3.9] (1'-112') -IGKC*01 (113'-219')]; dimère (228-228'':231-231'')-
                           bisdisulfure

 ganitumab                 inmunoglobulina G1-kappa, anti-[Homo sapiens IGF1R (receptor del
                           factor de crecimiento 1 análogo a la insulina, IGF1-R, IGF-1R,
                           CD221)], anticuerpo monoclonal de Homo sapiens;
                           cadena pesada gamma1 (1-449) [Homo sapiens VH (IGHV4-4*02
                           (100.00%) -(IGHD)-IGHJ3*02) [9.7.12] (1-119) -IGHG1*01 (120-
                           449)], (222-219')-disulfuro con la cadena ligera kappa (1'-219')
                           [Homo sapiens V-KAPPA (IGKV2-28*01 (95.00%) -IGKJ1*01)
                           [11.3.9] (1'-112') -IGKC*01 (113'-219')]; dímero (228-228'':231-231'')-
                           bisdisulfuro

                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLQESGPG LVKPSGTLSL TCAVSGGSIS                  SSNWWSWVRQ       PPGKGLEWIG        50
                           EIYHSGSTNY NPSLKSRVTI SVDKSKNQFS                  LKLSSVTAAD       TAVYYCARWT       100
                           GRTDAFDIWG QGTMVTVSSA STKGPSVFPL                  APSSKSTSGG       TAALGCLVKD       150
                           YFPEPVTVSW NSGALTSGVH TFPAVLQSSG                  LYSLSSVVTV       PSSSLGTQTY       200
                           ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP                  CPAPELLGGP       SVFLFPPKPK       250
                           DTLMISRTPE VTCVVVDVSH EDPEVKFNWY                  VDGVEVHNAK       TKPREEQYNS       300
                           TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL                  PAPIEKTISK       AKGQPREPQV       350
                           YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA                  VEWESNGQPE       NNYKTTPPVL       400
                           DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM                  HEALHNHYTQ       KSLSLSPGK        449

                           Light chain / Chaîne légère / Cadena ligera
                           DVVMTQSPLS LPVTPGEPAS ISCRSSQSLL                  HSNGYNYLDW       YLQKPGQSPQ 50
                           LLIYLGSNRA SGVPDRFSGS GSGTDFTLKI                  SRVEAEDVGV       YYCMQGTHWP 100
                           LTFGQGTKVE IKRTVAAPSV FIFPPSDEQL                  KSGTASVVCL       LNNFYPREAK 150
                           VQWKVDNALQ SGNSQESVTE QDSKDSTYSL                  SSTLTLSKAD       YEKHKVYACE 200
                           VTHQGLSSPV TKSFNRGEC                                                          219

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96        146-202       263-323  369-427
                                    22''-96'' 146''-202'' 263''-323'' 369''-427''
                           Intra-L 23'-93'      139'-199'
                                    23'''-93''' 139'''-199'''
                           Inter-H-L 222-219' 222''-219'''
                           Inter-H-H 228-228'' 231-231''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           299, 299''




 gataparsenum
 gataparsen                all-P-ambo-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-
                           O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-
                           methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioguanylyl-
                           (3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-
                           (3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-
                           thiothymidylyl-(3'→5')-2'-deoxy-5-methyl-P-thioucytidylyl-(3'→5')-P-
                           thiothymidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-P-
                           thiothymidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-O-(2-
                           methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-
                           thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-
                           (3'→5')-2'-O-(2-methoxyethyl)-5-methyluridine




66
WHO Drug Information, Vol. 25, No. 1, 2011                                                       Recommended INN: List 65


 gataparsen                                  tout-P-ambo-2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiouridylyl-(3'→5')-
                                             2'-O-(2-méthoxyéthyl)-P-thioguanylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-
                                             5-méthyl-P-thiouridylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-P-thioguanylyl-
                                             (3'→5')-2'-déoxy-5-méthyl-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-
                                             (3'→5')-2'-déoxy-P-thioadénylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-
                                             thiothymidylyl-(3'→5')-2'-déoxy-5-méthyl-P-thiocytidylyl-(3'→5')-P-
                                             thiothymidylyl-(3'→5')-2'-déoxy-P-thioguanylyl-(3'→5')-P-
                                             thiothymidylyl-(3'→5')-2'-déoxy-P-thioguanylyl-(3'→5')-2'-O-(2-
                                             méthoxyéthyl)-P-thioadénylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-P-
                                             thioadénylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiouridylyl-
                                             (3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyluridine

 gataparsén                                  todo-P-ambo-2'-O-(2-metoxietil)-5-metil-P-tiouridilil-(3'→5')-2'-O-(2-
                                             metoxietil)-P-tioguanilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-P-tiouridilil-
                                             (3'→5')-2'-O-(2-metoxietil)-P-tioguanilil-(3'→5')-2'-desoxi-5-metil-P-
                                             tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-
                                             P-tiotimidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-5-metil-P-tiocitidilil-
                                             (3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-P-
                                             tiotimidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-O-(2-metoxietil)-P-
                                             tioadenilil-(3'→5')-2'-O-(2-metoxietil)-P-tioadenilil-(3'→5')-2'-O-(2-
                                             metoxietil)-5-metil-P-tiouridilil-(3'→5')-2'-O-(2-metoxietil)-5-
                                             metiluridina

                                             C204H278N59O111P17S17

                                             (3'→5')d(P-thio)(rU-rG-rU-rG-C-T-A-T-T-C-T-G-T-G-rA-rA-rU-rU)

                                             Modified nucleosides / Nucléosides modifiés / Nucleosidos modificados:
                                             A                N            G      H2 N
                                                            N           NH2                          NH
                                             OH                                              N             O
                                                    O       N       N         OH
                                                                                    O        N       N
                                                                    OCH3
                                              HO        O                                             OCH3
                                                                               HO        O
                                                   U            H
                                                        O       N       O          C O           N        NH2
                                             OH                               OH
                                                    O       N                       O    N
                                                                        CH3                               CH3
                                                                    OCH3
                                              HO        O                     HO        OH



 gemigliptinum
 gemigliptin                                 1-{(2S)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-dihydropyrido[3,4-
                                             d]pyrimidin-7(6H)-yl]-4-oxobutyl}-5,5-difluoropiperidin-2-one

 gémigliptine                                1-{(2S)-2-amino-4-[2,4-bis(trifluorométhyl)-5,8-dihydropyrido[3,4-
                                             d]pyrimidin-7(6H)-yl]-4-oxobutyl}-5,5-difluoropipéridin-2-one

 gemigliptina                                1-{(2S)-2-amino-4-[2,4-bis(trifluorometil)-5,8-dihidropirido[3,4-
                                             d]pirimidin-7(6H)-il]-4-oxobutil}-5,5-difluoropiperidin-2-ona




                                                                                                                           67
Recommended INN: List 65                                            WHO Drug Information, Vol. 25, No. 1, 2011


                                 C18H19F8N5O2

                                                 CF3

                                             N                                    O
                                                            N
                                 F3C             N                            N
                                                                O   H   NH2

                                                                              F       F



 iniparibum
 iniparib                        4-iodo-3-nitrobenzamide

 iniparib                        4-iodo-3-nitrobenzamide

 iniparib                        4-iodo-3-nitrobenzamida

                                 C7H5IN2O3

                                       I

                                                            NH2
                                 O2N
                                                       O



 insulinum tregopilum
                                     6,29B
 insulin tregopil                N         -(4,7,10,13-tetraoxatetradecanoyl)human insulin
                                     6,29B
 insuline trégopil               N         -(4,7,10,13-tétraoxatétradécanoyl)insuline humaine
                                     6,29B
 insulina tregopilo              N         -(4,7,10,13-tetraoxatetradecanoil)insulina humana

                                 C267H401N65O82S6

                                  H Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu
                                                                                          10
                                       Glu Asn Tyr Cys Asn OH
                                                       20

                                  H Phe Val Asn Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr
                                                                                          10
                                       Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro Lys Thr OH
                                                   20                                 N6    30
                                                          O             O
                                                      H3C         O             O         O



                           131
 ioflubenzamidum ( I)
                 131                                                                                 131
 ioflubenzamide ( I)             N-[2-(diethylamino)ethyl]-4-(4-fluorobenzamido)-5-[                   I]iodo-
                                 2-methoxybenzamide
                     131                                                                             131
 ioflubenzamide (      I)        N-[2-(diéthylamino)éthyl]-4-(4-fluorobenzamido)-5-[                   I]iodo-
                                 2-méthoxybenzamide
                     131                                                                       131
 ioflubenzamida (      I)        N-[2-(dietilamino)etil]-4-(4-fluorobenzamido)-5-[               I]iodo-
                                 2-metoxibenzamida




68
WHO Drug Information, Vol. 25, No. 1, 2011                                                           Recommended INN: List 65


                                                       131
                                             C21H25F     IN3O3

                                                                                                     CH3
                                                                                    O
                                                              131
                                                              [   I]                             N       CH3
                                                             O                          N
                                                                                        H

                                                                  N                 OCH3
                                                                  H
                                             F



 ioforminolum
 ioforminol                                  all-ambo-5,5'-[2-hydroxypropane-
                                             1,3-diylbis(formylazanediyl)]bis[N,N'-bis(2,3-dihydroxypropyl)-
                                             2,4,6-triiodobenzene-1,3-dicarboxamide]

 ioforminol                                  tout-ambo-5,5'-[2-hydroxypropane-
                                             1,3-diylbis(formylazanediyl)]bis[N,N'-bis(2,3-dihydroxypropyl)-
                                             2,4,6-triiodobenzène-1,3-dicarboxamide]

 ioforminol                                  todo-ambo-5,5'-[2-hidroxipropano-1,3-diilbis(formilazanodiil)]bis[N,N'-
                                             bis(2,3-dihidroxipropil)-2,4,6-triiodobenceno-1,3-dicarboxamida]

                                             C33H40I6N6O15

                                                              OH                                                     OH
                                                                        H                                    H
                                                   HO                   N       O                    O       N            OH

                                                                    I               I            I               I
                                                     OH                                                                   OH
                                                              H                                                      H
                                             HO               N                                                      N         OH
                                                                                    N            N
                                                                    O       I               OH           I       O
                                                                                O                    O



 ipragliflozinum
 ipragliflozin                               (1S)-1,5-anhydro-1-C-{3-[(1-benzothiophen-2-yl)methyl]-
                                             4-fluorophenyl}-D-glucitol

 ipragliflozine                              (1S)-1,5-anhydro-1-C-{3-[(1-benzothiophén-2-yl)méthyl]-
                                             4-fluorophényl}-D-glucitol

 ipragliflozina                              (1S)-1,5-anhidro-1-C-{3-[(1-benzotiofen-2-il)metil]-4-fluorofenil}-
                                             D-glucitol
                                             C21H21FO5S




                                                         S
                                                             F

                                             HO

                                                         O
                                                  OH
                                             HO
                                                         OH




                                                                                                                                    69
Recommended INN: List 65                             WHO Drug Information, Vol. 25, No. 1, 2011




 itarnafloxinum
 itarnafloxin              5-fluoro-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-3-oxo-6-[(3RS)-3-
                           (pyrazin-2-yl)pyrrolidin-1-yl]-3H-benzo[b]pyrido[3,2,1-kl]phenoxazine-
                           2-carboxamide

 itarnafloxine             5-fluoro-N-{2-[(2S)-1-méthylpyrrolidin-2-yl]éthyl}]-3-oxo-6-[3-(pyrazin-
                           2-yl)pyrrolidin-1-yl]-3H-benzo[b]pyrido[3,2,1-kl]phénoxazine-
                           2-carboxamide

 itarnafloxina             5-fluoro-N-{2-[(2S)-1-metilpirrolidin-2-il]etil}-3-oxo-6-[(3RS)-3-
                           (pirazin-2-il)pirrolidin-1-il]-3H-benzo[b]pirido[3,2,1-kl]fenoxazina-
                           2-carboxamida

                           C35H33FN6O3


                                                                 and epimer at C*
                                                                 et l'épimère en C*
                                  H             O                y el epímero al C*
                              N       *
                                          N           N
                                                                 H
                              N                                  N
                                          F
                                                                        H     N
                                                      O      O
                                                                              CH3



 itolizumabum #
 itolizumab                immunoglobulin G1-kappa, anti-[Homo sapiens CD6 (Tp120, T12)],
                           humanized monoclonal antibody;
                           gamma1 heavy chain (1-449) [humanized VH (Homo sapiens
                           IGHV3-21*08 (83.70%) -(IGHD)-IGHJ5*01) [8.8.12] (1-119) -Homo
                           sapiens IGHG1*01 (120-449)], (222-214')-disulfide with kappa light
                           chain (1'-214') [humanized V-KAPPA (Homo sapiens IGKV1-17*01
                           (76.80%) -IGKJ2*01 F118>L, Q120>S) [6.3.9] (1'-107') -Homo
                           sapiens IGKC*01 (108'-214')]; (228-228":231-231")-bisdisulfide
                           dimer

 itolizumab                immunoglobuline G1-kappa, anti-[Homo sapiens CD6 (Tp120, T12)],
                           anticorps monoclonal humanisé;
                           chaîne lourde gamma1 (1-449) [VH humanisé (Homo sapiens
                           IGHV3-21*08 (83.70%) -(IGHD)-IGHJ5*01) [8.8.12] (1-119) -Homo
                           sapiens IGHG1*01 (120-449)], (222-214')-disulfure avec la chaîne
                           légère kappa (1'-214') [V-KAPPA humanisé (Homo sapiens IGKV1-
                           17*01 (76.80%) -IGKJ2*01 F118>L, Q120>S) [6.3.9] (1'-107') -Homo
                           sapiens IGKC*01 (108'-214')]; dimère (228-228":231-231")-
                           bisdisulfure

 itolizumab                inmunoglobulina G1-kappa, anti-[Homo sapiens CD6 (Tp120, T12)],
                           anticuerpo monoclonal humanizado;
                           cadena pesada gamma1 (1-449) [VH humanizado (Homo sapiens
                           IGHV3-21*08 (83.70%) -(IGHD)-IGHJ5*01) [8.8.12] (1-119) -Homo
                           sapiens IGHG1*01 (120-449)], (222-214')-disulfuro con la cadena
                           ligera kappa (1'-214') [V-KAPPA humanizado (Homo sapiens IGKV1-
                           17*01 (76.80%) -IGKJ2*01 F118>L, Q120>S) [6.3.9] (1'-107') -Homo
                           sapiens IGKC*01 (108'-214')]; dímero (228-228":231-231")-
                           bisdisulfuro




70
WHO Drug Information, Vol. 25, No. 1, 2011                                                           Recommended INN: List 65




                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             EVQLVESGGG LVKPGGSLKL SCAASGFKFS                  RYAMSWVRQA       PGKRLEWVAT        50
                                             ISSGGSYIYY PDSVKGRFTI SRDNVKNTLY                  LQMSSLRSED       TAMYYCARRD       100
                                             YDLDYFDSWG QGTLVTVSSA STKGPSVFPL                  APSSKSTSGG       TAALGCLVKD       150
                                             YFPEPVTVSW NSGALTSGVH TFPAVLQSSG                  LYSLSSVVTV       PSSSLGTQTY       200
                                             ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP                  CPAPELLGGP       SVFLFPPKPK       250
                                             DTLMISRTPE VTCVVVDVSH EDPEVKFNWY                  VDGVEVHNAK       TKPREEQYNS       300
                                             TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL                  PAPIEKTISK       AKGQPREPQV       350
                                             YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA                  VEWESNGQPE       NNYKTTPPVL       400
                                             DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM                  HEALHNHYTQ       KSLSLSPGK        449

                                             Light chain / Chaîne légère / Cadena ligera
                                             DIQMTQSPSS LSASVGDRVT ITCKASRDIR                  SYLTWYQQKP       GKAPKTLIYY 50
                                             ATSLADGVPS RFSGSGSGQD YSLTISSLES                  DDTATYYCLQ       HGESPFTLGS 100
                                             GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                                             DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                                             LSSPVTKSFN RGEC                                                               214

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H 22-96        146-202       263-323  369-427
                                                       22''-96'' 146''-202'' 263''-323'' 369''-427''
                                             Intra-L 23'-88' 134'-194'
                                                      23'''-88''' 134'''-194'''
                                             Inter-H-L 222-214' 222''-214'''
                                             Inter-H-H 228-228'' 231-231''

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             299, 299''



 lorvotuzumabum mertansinum #
 lorvotuzumab mertansine                     immunoglobulin G1-kappa, anti-[Homo sapiens NCAM1 (neural cell
                                             adhesion molecule 1, CD56, NCAM-1)], humanized monoclonal
                                             antibody conjugated to maytansinoid DM1;
                                             gamma1 heavy chain (1-448) [humanized VH (Homo sapiens
                                             IGHV3-30*03 (91.80%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -Homo
                                             sapiens IGHG1*01 (119-448)], (221-219')-disulfide with kappa light
                                             chain (1'-219') [humanized V-KAPPA (Homo sapiens IGKV2-30*02
                                             (92.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01
                                             (113'-219')]; (227-227":230-230")-bisdisulfide dimer; conjugated, on
                                             an average of 3 to 4 lysyl, to maytansinoid DM1 via a thiopentanoate
                                             linker
                                             For the mertansine part, please refer to the document "INN for
                                             pharmaceutical substances: Names for radicals, groups and others"*

 lorvotuzumab mertansine                     immunoglobuline G1-kappa, anti-[Homo sapiens NCAM1 (molécule
                                             d'adhésion 1 de cellule neurale, CD56, NCAM-1)], anticorps
                                             monoclonal humanisé conjugué au maytansinoïde DM1; chaîne
                                             lourde gamma1 (1-448) [VH humanisé (Homo sapiens IGHV3-30*03
                                             (91.80%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -Homo sapiens
                                             IGHG1*01 (119-448)], (221-219')-disulfure avec la chaîne légère
                                             kappa (1'-219') [V-KAPPA humanisé (Homo sapiens IGKV2-30*02
                                             (92.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01
                                             (113'-219')]; dimère (227-227":230-230")-bisdisulfure; conjugué, sur
                                             3 à 4 lysyl en moyenne, au maytansinoïde DM1 via un linker
                                             thiopentanoate
                                             Pour la partie mertansine, veuillez vous référer au document "INN for
                                             pharmaceutical substances: Names for radicals, groups and
                                             others"*.




                                                                                                                                         71
Recommended INN: List 65                                    WHO Drug Information, Vol. 25, No. 1, 2011


 lorvotuzumab mertansina   inmunoglobulina G1-kappa, anti-[Homo sapiens NCAM1 (molécula
                           de adhesión 1 de celula neural, CD56, NCAM-1)], anticuerpo
                           monoclonal humanizado conjugado con maitansinoide DM1;
                           cadena pesada gamma1 (1-448) [VH humanizado (Homo sapiens
                           IGHV3-30*03 (91.80%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -Homo
                           sapiens IGHG1*01 (119-448)], (221-219')-disulfuro con la cadena
                           ligera kappa (1'-219') [V-KAPPA humanizado (Homo sapiens IGKV2-
                           30*02 (92.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens
                           IGKC*01 (113'-219')]; dimero (227-227":230-230")-bisdisulfuro;
                           conjugado, en 3 a 4 residuos lisil por término medio, con
                           maitansinoide DM1 con un conector tiopentanoato
                           Por la parte mertansina, por favor, vaya al documento "INN for
                           pharmaceutical substances: Names for radicals, groups & others"*.


                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLVESGGG VVQPGRSLRL SCAASGFTFS                  SFGMHWVRQA       PGKGLEWVAY        50
                           ISSGSFTIYY ADSVKGRFTI SRDNSKNTLY                  LQMNSLRAED       TAVYYCARMR       100
                           KGYAMDYWGQ GTLVTVSSAS TKGPSVFPLA                  PSSKSTSGGT       AALGCLVKDY       150
                           FPEPVTVSWN SGALTSGVHT FPAVLQSSGL                  YSLSSVVTVP       SSSLGTQTYI       200
                           CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC                  PAPELLGGPS       VFLFPPKPKD       250
                           TLMISRTPEV TCVVVDVSHE DPEVKFNWYV                  DGVEVHNAKT       KPREEQYNST       300
                           YRVVSVLTVL HQDWLNGKEY KCKVSNKALP                  APIEKTISKA       KGQPREPQVY       350
                           TLPPSRDELT KNQVSLTCLV KGFYPSDIAV                  EWESNGQPEN       NYKTTPPVLD       400
                           SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH                  EALHNHYTQK       SLSLSPGK         448

                           Light chain / Chaîne légère / Cadena ligera
                           DVVMTQSPLS LPVTLGQPAS ISCRSSQIII                  HSDGNTYLEW       FQQRPGQSPR 50
                           RLIYKVSNRF SGVPDRFSGS GSGTDFTLKI                  SRVEAEDVGV       YYCFQGSHVP 100
                           HTFGQGTKVE IKRTVAAPSV FIFPPSDEQL                  KSGTASVVCL       LNNFYPREAK 150
                           VQWKVDNALQ SGNSQESVTE QDSKDSTYSL                  SSTLTLSKAD       YEKHKVYACE 200
                           VTHQGLSSPV TKSFNRGEC                                                          219

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96        145-201       262-322  368-426
                                    22''-96'' 145''-201'' 262''-322'' 368''-426''
                           Intra-L 23'-93'      139'-199'
                                    23'''-93''' 139'''-199'''
                           Inter-H-L 221-219' 221''-219'''
                           Inter-H-H 227-227'' 230-230''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           298, 298''



 maraciclatidum
                            6
 maraciclatide             N -(5-{[5-{[3-(hydroxyimino)-2-methylbutan-2-yl]amino}-3-(2-{[3-
                           (hydroxyimino)-2-methylbutan-2-yl]amino}ethyl)pentyl]amino}-
                                               2
                           5-oxopentanoyl)-N -(2-sulfanylacetyl)-L-lysyl-L-cysteinyl-
                           L-arginylglycyl-L-α-aspartyl-L-cysteinyl-L-phenylalanyl-N-(17-amino-
                           13,17-dioxo-3,6,9,15-tetraoxa-12-azaheptadecyl)-L-cysteinamide
                           cyclic (2→6)-disulfide cyclic (1→8)-thioether
                                                                                                         6
 maraciclatide             (2→6)-disulfure cyclique et (1→8)-thioéther cyclique du N -(5-{[5-{[3-
                           (hydroxyimino)-2-méthylbutan-2-yl]amino}-3-(2-{[3-(hydroxyimino)-
                           2-méthylbutan-2-yl]amino}éthyl)pentyl]amino}-5-oxopentanoyl)-
                             2
                           N -(2-sulfanylacétyl)-L-lysyl-L-cystéinyl-L-arginylglycyl-L-α-aspartyl-
                           L-cystéinyl-L-phénylalanyl-1-N-(17-amino-13,17-dioxo-3,6,9,15-
                           tétraoxa-12-azaheptadécyl)-L-cystéinamide
                                                                                                6
 maraciclatida             (2→6)-disulfuro cíclico y (1→8)-tioéter cíclico del N -(5-{[5-{[3-
                           (hidroxiimino)-2-metilbutan-2-il]amino}-3-(2-{[2-(hidroxiimino)-
                           2-metilbutan-2-il]amino}etil)pentil]amino}-5-oxopentanoil)-
                             2
                           N -(2-sulfanilacetil)-L-lisil-L-cisteinil-L-ar3inilglicil-L-α-aspartil-
                           L-cisteinil-L-fenilalanil-1-N-(17-amino-13,17-dioxo-3,6,9,15-tetraoxa-
                           12-azaheptadecil)-L-cisteinamida




72
WHO Drug Information, Vol. 25, No. 1, 2011                                                                  Recommended INN: List 65


                                             C72H120N20O21S3

                                                                           O                 O
                                                                                     O                      O
                                                                 H2N                             N                        O
                                                                                                 H
                                                                                                                                  O
                                                                                         S                                H

                                                           Lys       Cys       Arg   Gly     Asp     Cys    Phe       N           N
                                                   O                                                                  H           H
                                                        N6                      O                                             O

                                                       O                             NH

                                                       H3C CH3                               H3C CH3
                                             HO                                                             OH
                                                   N                                                    N
                                                                 N                           N
                                                                 H                           H
                                                       CH3                                           CH3



 metformini glycinas
 metformin glycinate                         N,N-dimethyl-1,2,3-triimidodicarbonic diamide glycinate (1:1)

 glycinate de metformine                     glycinate du diamide N,N-diméthyl-1,2,3-triimidodicarbonique (1:1)

 glicinato de metformina                     glicinato de la diamida N,N-dimetil-1,2,3-triimidodicarbóníco (1:1)

                                             C4H11N5 . C2H5NO2

                                                   NH        NH
                                                                         CH3
                                             H2N        N         N              .   H2N         CO2H
                                                        H
                                                                  CH3



 mibampatorum
 mibampator                                  N-[(2R)-2-{4'-[2-(methanesulfonamido)ethyl][1,1'-biphenyl]-
                                             4-yl}propyl]propane-2-sulfonamide

 mibampator                                  N-[(2R)-2-{4'-[2-(méthanesulfonamido)éthyl][1,1'-biphényl]-
                                             4-yl}propyl]propane-2-sulfonamide

 mibampator                                  N-[(2R)-2-{4'-[2-(metanosulfonamido)etil][1,1'-bifenil]-
                                             4-il}propil]propano-2-sulfonamida

                                             C21H30N2O4S2
                                                                                                             H
                                                                                                             N        CH3
                                                                                                                  S
                                                                                                                O O
                                                  O O
                                             H3C   S
                                                     N
                                                     H
                                                 CH3                 H     CH3




                                                                                                                                      73
Recommended INN: List 65                               WHO Drug Information, Vol. 25, No. 1, 2011


 navitoclaxum
 navitoclax                 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-
                            1-yl]methyl}piperazin-1-yl)-N-(4-{[(2R)-4-(morpholin-4-yl)-
                            1-(phenylsulfanyl)butan-2-yl]amino}-
                            3-(trifluoromethanesulfonyl)benzenesulfonyl]benzamide

 navitoclax                 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-
                            1-yl]methyl}piperazin-1-yl)-N-(4-{[(2R)-4-(morpholin-4-yl)-
                            1-(phenylsulfanyl)butan-2-yl]amino}-
                            3-(trifluoromethanesulfonyl)benzenesulfonyl]benzamide

 navitoclax                 4-(4-{[2-(4- clorofenil)-5,5- dimetilciclohex -1-en-1-il]metil}piperazin-
                            1-il)-N-(4-{[(2R)-1-(fenilsulfanil)-4-(morfolin-4-il)-butan-2-il]amino}-
                            3-(trifluorometanosulfonil)bencenosulfonil]benzamida

                            C47H55ClF3N5O6S3

                                                             O    O O              O O
                                                                     S              S
                            H3 C    CH3                          N                       CF3
                                                                 H
                                                N                                   NH
                                          N                                    H
                                                                           S
                                                                                           N
                                                                                               O

                                   Cl




 nonacogum beta pegolum #
 nonacog beta pegol         pegylated human blood coagulation factor IX;
                            human coagulation factor IX (EC 3.4.21.22, Christmas factor, plasma
                            thromboplastin component), en average of one sialyl unit of the
                            N-linked carbohydrates are 5-N-[N-({2,3-bis[ω-
                            methoxypoly(oxyethane-1,2-diyl)]propoxy}carbonyl)glycyl]-
                            5-N-deacetyl

 nonacog bêta pégol         facteur IX humain de coagulation sanguine, pégylé;
                            facteur IX humain de coagulation (EC 3.4.21.22, facteur Christmas,
                            facteur antihémophile B) dont quelques unités sialyl, en moyenne
                            une par molécule d'enzyme, de la partie N-glycosyl sont 5-N-[N-
                            ({2,3-bis[ω-méthoxypoly(oxyéthylène)]propoxy}carbonyl)glycyl]-
                            5-N-désacétyl

 nonacog beta pegol         factor IX humano de coagulación sanguínea, pegilado;
                            factor IX humano de coagulación (EC 3.4.21.22, factor Christmas,
                            factor antihemofilico B) algunas de cuyas unidades sialil, una por
                            molécula de enzima, por término medio, de la fracción N-glicosil son
                            5-N-[N-({2,3-bis[ω-metoxipoli(oxietilen)]propoxi}carbonil)glicil]-
                            5-N-desacetil




74
WHO Drug Information, Vol. 25, No. 1, 2011                                                                  Recommended INN: List 65



                                             YNSGKLEEFV        QGNLERECME         EKCSFEEARE        VFENTERTTE        FWKQYVDGDQ      50
                                             CESNPCLNGG        SCKDDINSYE         CWCPFGFEGK        NCELDVTCNI        KNGRCEQFCK      100
                                             NSADNKVVCS        CTEGYRLAEN         QKSCEPAVPF        PCGRVSVSQT        SKLTRAEAVF      150
                                             PDVDYVNSTE        AETILDNITQ         STQSFNDFTR        VVGGEDAKPG        QFPWQVVLNG      200
                                             KVDAFCGGSI        VNEKWIVTAA         HCVETGVKIT        VVAGEHNIEE        TEHTEQKRNV      250
                                             IRIIPHHNYN        AAINKYNHDI         ALLELDEPLV        LNSYVTPICI        ADKEYTNIFL      300
                                             KFGSGYVSGW        GRVFHKGRSA         LVLQYLRVPL        VDRATCLRST        KFTIYNNMFC      350
                                             AGFHEGGRDS        CQGDSGGPHV         TEVEGTSFLT        GIISWGEECA        MKGKYGIYTK      400
                                             VSRYVNWIKE        KTKLT                                                                  415

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             18-23     51-62      56-71     73-82      88-99      95-109
                                             111-124 132-289 206-222 336-350 361-389
                                             Modified residues / Résidus modifiés / Residuos modifícados

                                                                  E                                 HO2C        H    NH2
                                                  7-8-15-17-20-21-26-27-30-33-36-40
                                                            4-carboxyGlu                        HO 2C                  CO 2H
                                             Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
                                                Asn-157   Asn-167
                                                R→3-β-Gal→3-β-Gl-N→2-α-Man→6-
                                                                                                   β-Man→4-β-Gl-N→4-β-Gl-N→N
                                               R'→3-β-Gal→3-β-Gl-N→2-α-Man→3-
                                             R = α-Sia, R' = α-Sia or PEG-α-Sia or R' = α-Sia, R = α-Sia or PEG-α-Sia
                                                Gal = D-galactopyranosyl
                                                Gl-N = 2-(acetylamino)-2-deoxy-D-glucopyranosyl
                                                Man = D-mannopyranosyl
                                                PEG- = O-[α-methylpoly(oxyethylene) hydrogen phosphate]
                                                Sia = 5-N-acetyl-α-neuramin-2-yl

                                                Other positions of post-translational modifications:
                                                partial-hydroxylation of Asp64; O-linked glycosylation on positions Ser53 and Ser61,
                                                partially O-linked glycosylation on positions Thr159 and Thr169

                                                Autres positions de modifications post-traductionelles:
                                                hydroxylation partielle de Asp64; glycosylation O-liée sur les positions Sér53 et Sér61,
                                                glycosylation partielle O-liée sur les positions Thr159 et Thr169

                                                Otras posiciones de modificaciones post-traducción
                                                hidroxilación parcial de Asp64; glicosilación O-ligada en las posiciones Ser53 y Ser61,
                                                glicosilación parcial O-ligada en las posiciones Thr159 y Thr169



 obinutuzumabum #
 obinutuzumab                                immunoglobulin G1, anti-[Homo sapiens CD20 (membrane-spanning
                                             4-domains subfamily A member 1, MS4A1, B lymphocyte surface
                                             antigen B1, Leu-16, Bp35)], humanized monoclonal antibody,
                                             GA101;
                                             gamma1 heavy chain (1-448) [humanized VH (Homo sapiens
                                             FR/Mus musculus CDR, Homo sapiens IGHJ4*01) [8.8.12] (1-119) -
                                             Homo sapiens IGHG1*01 (120-448)], (222-219')-disulfide with kappa
                                             light chain (1'-219') [humanized V-KAPPA (Homo sapiens FR/Mus
                                             musculus CDR, Homo sapiens IGKJ4*01) [11.3.9] (1'-112') -Homo
                                             sapiens IGKC*01 (113'-219')]; (228-228'':231-231'')-bisdisulfide
                                             dimer
                                             immunomodulator

 obinutuzumab                                immunoglobuline G1, anti-[Homo sapiens CD20 (membre 1 de la
                                             sous-famille A à 4 domaines transmembranaires, MS4A1, antigène
                                             de surface B1 des lymphocytes B, Leu-16, Bp35)], anticorps
                                             monoclonal humanisé, GA101;
                                             chaîne lourde gamma1 (1-448) [VH humanisé (Homo sapiens
                                             FR/Mus musculus CDR, Homo sapiens IGHJ4*01) [8.8.12] (1-119) -
                                             Homo sapiens IGHG1*01 (120-448)], (222-219')-disulfure avec la
                                             chaîne légère kappa (1'-219') [V-KAPPA humanisé (Homo sapiens
                                             FR/Mus musculus CDR, Homo sapiens IGKJ4*01) [11.3.9] (1'-112') -
                                             Homo sapiens IGKC*01 (113'-219')]; dimère (228-228'':231-231'')-
                                             bisdisulfure
                                             immunomodulateur


                                                                                                                                            75
Recommended INN: List 65                                             WHO Drug Information, Vol. 25, No. 1, 2011


 obinutuzumab              inmunoglobulina G1, anti-[Homo sapiens CD20 (miembro 1 de la
                           sub-familia A de 4 dominios transmembranarios, MS4A1, antígeno
                           de superficie B1 de los linfocitos B, Leu-16, Bp35)], anticuerpo
                           monoclonal humanizado, GA101;
                           cadena pesada gamma1 (1-448) [VH humanizada (Homo sapiens
                           FR/Mus musculus CDR, Homo sapiens IGHJ4*01) [8.8.12] (1-119) -
                           Homo sapiens IGHG1*01 (120-448)], (222-219')-disulfuro con la
                           cadena ligera kappa (1'-219') [V-KAPPA humanizada (Homo sapiens
                           FR/Mus musculus CDR, Homo sapiens IGKJ4*01) [11.3.9] (1'-112') -
                           Homo sapiens IGKC*01 (113'-219')]; dímero (228-228'':231-231'')-
                           bisdisulfuro
                           inmunomodulador


                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLVQSGAE            VKKPGSSVKV              SCKASGYAFS            YSWINWVRQA            PGQGLEWMGR   50
                           IFPGDGDTDY            NGKFKGRVTI              TADKSTSTAY            MELSSLRSED            TAVYYCARNV   100
                           FDGYWLVYWG            QGTLVTVSSA              STKGPSVFPL            APSSKSTSGG            TAALGCLVKD   150
                           YFPEPVTVSW            NSGALTSGVH              TFPAVLQSSG            LYSLSSVVTV            PSSSLGTQTY   200
                           ICNVNHKPSN            TKVDKKVEPK              SCDKTHTCPP            CPAPELLGGP            SVFLFPPKPK   250
                           DTLMISRTPE            VTCVVVDVSH              EDPEVKFNWY            VDGVEVHNAK            TKPREEQYNS   300
                           TYRVVSVLTV            LHQDWLNGKE              YKCKVSNKAL            PAPIEKTISK            AKGQPREPQV   350
                           YTLPPSRDEL            TKNQVSLTCL              VKGFYPSDIA            VEWESNGQPE            NNYKTTPPVL   400
                           DSDGSFFLYS            KLTVDKSRWQ              QGNVFSCSVM            HEALHNHYTQ            KSLSLSPGK    449

                           Light chain / Chaîne légère / Cadena ligera
                           DIVMTQTPLS            LPVTPGEPAS              ISCRSSKSLL            HSNGITYLYW            YLQKPGQSPQ   50'
                           LLIYQMSNLV            SGVPDRFSGS              GSGTDFTLKI            SRVEAEDVGV            YYCAQNLELP   100'
                           YTFGGGTKVE            IKRTVAAPSV              FIFPPSDEQL            KSGTASVVCL            LNNFYPREAK   150'
                           VQWKVDNALQ            SGNSQESVTE              QDSKDSTYSL            SSTLTLSKAD            YEKHKVYACE   200'
                           VTHQGLSSPV            TKSFNRGEC                                                                        219'

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           22-96      22''-96''    23'-93'     23'''-93''' 139'-199' 139'''-199''' 146-202 146''-202''
                           219'-222 219'''-222'' 228-228'' 231-231'' 263-323 263''-323'' 369-427 369''-427''

                           Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
                           Ser-53 Ser-61 Asn-157 Thr-159 Asn-167 Thr-169




 olaratumabum #
 olaratumab                immunoglobulin G1-kappa, anti-[Homo sapiens PDGFRA (platelet-
                           derived growth factor receptor alpha subunit, CD140a, PDGFR2)],
                           Homo sapiens monoclonal antibody;
                           gamma1 heavy chain (1-457) [Homo sapiens VH (IGHV4-39*01
                           (90.90%) -(IGHD)-IGHJ5*01 G119>D) [10.7.19] (1-127) -IGHG1*03
                           (128-457)], (230-214')-disulfide with kappa light chain (1'-214')
                           [Homo sapiens V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ1*01)
                           [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (236-236'':239-239'')-
                           bisdisulfide dimer

 olaratumab                immunoglobuline G1-kappa, anti-[Homo sapiens PDGFRA (sous-
                           unité alpha du récepteur du facteur de croissance dérivé des
                           plaquettes, CD140a, PDGFR2)], Homo sapiens anticorps
                           monoclonal;
                           chaîne lourde gamma1 (1-457) [Homo sapiens VH (IGHV4-39*01
                           (90.90%) -(IGHD)-IGHJ5*01 G119>D) [10.7.19] (1-127) -IGHG1*03
                           (128-457)], (230-214')-disulfure avec la chaîne légère kappa (1'-214')
                           [Homo sapiens V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ1*01)
                           [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (236-236'':239-239'')-
                           bisdisulfure




76
WHO Drug Information, Vol. 25, No. 1, 2011                                                           Recommended INN: List 65


  olaratumab                                 inmunoglobulina G1-kappa, anti-[Homo sapiens PDGFRA
                                             (subunidad alfa del receptor del factor de crecimiento derivado de
                                             las plaquetas, CD140a, PDGFR2)], Homo sapiens anticuerpo
                                             monoclonal;
                                             cadena pesada gamma1 (1-457) [Homo sapiens VH (IGHV4-39*01
                                             (90.90%) -(IGHD)-IGHJ5*01 G119>D) [10.7.19] (1-127) -IGHG1*03
                                             (128-457)], (230-214')-disulfuro con la cadena ligera kappa (1'-214')
                                             [Homo sapiens V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ1*01)
                                             [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimero (236-236'':239-239'')-
                                             bisdisulfuro

                                              Heavy chain / Chaîne lourde / Cadena pesada
                                              QLQLQESGPG LVKPSETLSL TCTVSGGSIN                  SSSYYWGWLR       QSPGKGLEWI        50
                                              GSFFYTGSTY YNPSLRSRLT ISVDTSKNQF                  SLMLSSVTAA       DTAVYYCARQ       100
                                              STYYYGSGNY YGWFDRWDQG TLVTVSSAST                  KGPSVFPLAP       SSKSTSGGTA       150
                                              ALGCLVKDYF PEPVTVSWNS GALTSGVHTF                  PAVLQSSGLY       SLSSVVTVPS       200
                                              SSLGTQTYIC NVNHKPSNTK VDKRVEPKSC                  DKTHTCPPCP       APELLGGPSV       250
                                              FLFPPKPKDT LMISRTPEVT CVVVDVSHED                  PEVKFNWYVD       GVEVHNAKTK       300
                                              PREEQYNSTY RVVSVLTVLH QDWLNGKEYK                  CKVSNKALPA       PIEKTISKAK       350
                                              GQPREPQVYT LPPSREEMTK NQVSLTCLVK                  GFYPSDIAVE       WESNGQPENN       400
                                              YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG                  NVFSCSVMHE       ALHNHYTQKS       450
                                              LSLSPGK                                                                             457

                                              Light chain / Chaîne légère / Cadena ligera
                                              EIVLTQSPAT LSLSPGERAT LSCRASQSVS                  SYLAWYQQKP       GQAPRLLIYD 50
                                              ASNRATGIPA RFSGSGSGTD FTLTISSLEP                  EDFAVYYCQQ       RSNWPPAFGQ 100
                                              GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                                              DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                                              LSSPVTKSFN RGEC                                                               214

                                              Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                              Intra-H 22-97        154-210       271-331  377-435
                                                       22''-97'' 154''-210'' 271''-331'' 377''-435''
                                              Intra-L 23'-88'      134'-194'
                                                       23'''-88''' 134'''-194'''
                                              Inter-H-L 230-214' 230''-214'''
                                              Inter-H-H 236-236'' 239-239''

                                              N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                              30, 30'', 307, 307''



 olokizumabum #
 olokizumab                                  immunoglobulin G4-kappa, anti-[Homo sapiens IL6 (interleukin 6; IL-
                                             6)], humanized monoclonal antibody;
                                             gamma4 heavy chain (1-447) [humanized VH (Homo sapiens
                                             IGHV3-72*01 (84.00%) -(IGHD)-IGHJ4*01) [8.10.11] (1-120) -Homo
                                             sapiens IGHG4*01 hinge S10(228)>P (121-447)], (134-214')-
                                             disulfide with kappa light chain (1'-214') [humanized V-KAPPA
                                             (Homo sapiens IGKV1-33*01 (84.20%) -IGKJ2*01) [6.3.9] (1'-107') -
                                             Homo sapiens IGKC*01 (108'-214')]; (226-226":229-229")-
                                             bisdisulfide dimer

 olokizumab                                  immunoglobuline G4-kappa, anti-[Homo sapiens Homo sapiens IL6
                                             (interleukine 6; IL-6)], anticorps monoclonal humanisé;
                                             chaîne lourde gamma4 (1-447) [VH humanisé (Homo sapiens
                                             IGHV3-72*01 (84.00%) -(IGHD)-IGHJ4*01) [8.10.11] (1-120) -Homo
                                             sapiens IGHG4*01 charnière S10(228)>P (121-447)], (134-214')-
                                             disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé
                                             (Homo sapiens IGKV1-33*01 (84.20%) -IGKJ2*01) [6.3.9] (1'-107') -
                                             Homo sapiens IGKC*01 (108'-214')]; dimère (226-226":229-229")-
                                             bisdisulfure




                                                                                                                                         77
Recommended INN: List 65                                      WHO Drug Information, Vol. 25, No. 1, 2011


 olokizumab                inmunoglobulina G4-kappa, anti-[Homo sapiens Homo sapiens IL6
                           (interleukina 6; IL-6)], anticuerpo monoclonal humanizado;
                           cadena pesada gamma4 (1-447) [VH humanizado (Homo sapiens
                           IGHV3-72*01 (84.00%) -(IGHD)-IGHJ4*01) [8.10.11] (1-120) -Homo
                           sapiens IGHG4*01 bisagra S10(228)>P (121-447)], (134-214')-
                           disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado
                           (Homo sapiens IGKV1-33*01 (84.20%) -IGKJ2*01) [6.3.9] (1'-107') -
                           Homo sapiens IGKC*01 (108'-214')]; dímero (226-226":229-229")-
                           bisdisulfuro

                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLVESGGG LVQPGGSLRL SCAASGFNFN                     DYFMNWVRQA    PGKGLEWVAQ        50
                           MRNKNYQYGT YYAESLEGRF TISRDDSKNS                     LYLQMNSLKT    EDTAVYYCAR       100
                           ESYYGFTSYW GQGTLVTVSS ASTKGPSVFP                     LAPCSRSTSE    STAALGCLVK       150
                           DYFPEPVTVS WNSGALTSGV HTFPAVLQSS                     GLYSLSSVVT    VPSSSLGTKT       200
                           YTCNVDHKPS NTKVDKRVES KYGPPCPPCP                     APEFLGGPSV    FLFPPKPKDT       250
                           LMISRTPEVT CVVVDVSQED PEVQFNWYVD                     GVEVHNAKTK    PREEQFNSTY       300
                           RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS                     SIEKTISKAK    GQPREPQVYT       350
                           LPPSQEEMTK NQVSLTCLVK GFYPSDIAVE                     WESNGQPENN    YKTTPPVLDS       400
                           DGSFFLYSRL TVDKSRWQEG NVFSCSVMHE                     ALHNHYTQKS    LSLSLGK          447

                           Light chain / Chaîne légère / Cadena ligera
                           DIQMTQSPSS LSASVGDRVT ITCQASQDIG                     ISLSWYQQKP    GKAPKLLIYN 50
                           ANNLADGVPS RFSGSGSGTD FTLTISSLQP                     EDFATYYCLQ    HNSAPYTFGQ 100
                           GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA                     SVVCLLNNFY    PREAKVQWKV 150
                           DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                     LSKADYEKHK    VYACEVTHQG 200
                           LSSPVTKSFN RGEC                                                               214

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-98 147-203              261-321  367-425
                                    22''-98'' 147''-203'' 261''-321'' 367''-425''
                           Intra-L 23'-88'      134'-194'
                                    23'''-88''' 134'''-194'''
                           Inter-H-L 134-214' 134''-214'''
                           Inter-H-H 226-226'' 229-229''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           297, 297''


 opicaponum
 opicapone                 2,5-dichloro-3-[5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl]-
                           4,6-dimethylpyridine N-oxide

 opicapone                 N-oxyde de 2,5-dichloro-3-[5-(3,4-dihydroxy-5-nitrophényl)-
                           1,2,4-oxadiazol-3-yl]-4,6-diméthylpyridine

 opicapona                 N-óxido de 2,5-dicloro-3-[5-(3,4-dihidroxi-5-nitrofenil)-
                           1,2,4-oxadiazol-3-il]-4,6-dimetilpiridina

                           C15H10Cl2N4O6

                                                       H3C           Cl
                                                  N
                                              O
                                                                          CH3
                           O2 N                    N             N
                                                         Cl          O
                            HO
                                      OH

 orantinibum
 orantinib                 3-(2,4-dimethyl-5-{[(3Z)-2-oxo-1,2-dihydro-3H-indol-
                           3-ylidene]methyl}-1H-pyrrol-3-yl)propanoic acid

 orantinib                 acide 3-(2,4-diméthyl-5-{[(3Z)-2-oxo-1,2-dihydro-3H-indol-
                           3-ylidène]méhyl}-1H-pyrrol-3-yl)propanoïque

 orantinib                 ácido 3-(2,4-dimetil-5-{[(3Z)-2-oxo-1,2-dihidro-3H-indol-
                           3-ilideno]metil}-1H-pirrol-3-il)propanoico


78
WHO Drug Information, Vol. 25, No. 1, 2011                                                                          Recommended INN: List 65


                                             C18H18N2O3
                                                          H
                                                          N
                                                                    O
                                                                         H         CH3
                                                                         N


                                                                                              CO2H
                                                                   H3C

 oxelumabum #
 oxelumab                                    immunoglobulin G1-kappa, anti-[Homo sapiens TNFSF4 (Tumor
                                             necrosis factor ligand superfamily member 4, OX40 ligand, OX-40L,
                                             TAX transcriptionally-activated glycoprotein 1, TXGP1, gp34,
                                             CD252], Homo sapiens monoclonal antibody;
                                             gamma1 heavy chain (1-449) [Homo sapiens VH (IGHV3-23*01
                                             (94.90%) -(IGHD)-IGHJ4*01 T122>A) [8.8.13] (1-120) -IGHG1*01
                                             K130>del (121-449)], (223-214')-disulfide with kappa light chain (1'-
                                             214') [Homo sapiens V-KAPPA (IGKV1D-16*01 (100.00%) -
                                             IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (229-229'':232-
                                             232'')-bisdisulfide dimer

 oxélumab                                    immunoglobuline G1-kappa, anti-[Homo sapiens TNFSF4 (membre
                                             4 de la superfamille des ligands du facteur de nécrose tumorale,
                                             ligand de OX40, OX40L, glycoprotéine 1 activée
                                             transcriptionellement par TAX, TXGP1, CD252], Homo sapiens
                                             anticorps monoclonal;
                                             chaîne lourde gamma1 (1-449) [Homo sapiens VH (IGHV3-23*01
                                             (94.90%) -(IGHD)-IGHJ4*01 T122>A) [8.8.13] (1-120) -IGHG1*01
                                             K130>del (121-449)], (223-214')-disulfure avec la chaîne légère
                                             kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1D-16*01 (100.00%)
                                             -IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (229-
                                             229'':232-232'')-bisdisulfure

 oxelumab                                    inmunoglobulina G1-kappa, anti-[Homo sapiens TNFSF4 (miembro 4
                                             de la superfamilia de ligandos del factor de necrosis tumoral, ligando
                                             de OX40, OX40L, glicoproteína 1 activada por transcripción por
                                             TAX, TXGP1, CD252 ], anticuerpo monoclonal de Homo sapiens;
                                             cadena pesada gamma1 (1-449) [Homo sapiens VH (IGHV3-23*01
                                             (94.90%) -(IGHD)-IGHJ4*01 T122>A) [8.8.13] (1-120) -IGHG1*01
                                             K130>del (121-449)], (223-214')-disulfuro con la cadena ligera
                                             kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1D-16*01 (100.00%)
                                             -IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimero (229-
                                             229'':232-232'')-bisdisulfuro

                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             EVQLLESGGG LVQPGGSLRL SCAASGFTFN                  SYAMSWVRQA       PGKGLEWVSI        50
                                             ISGSGGFTYY ADSVKGRFTI SRDNSRTTLY                  LQMNSLRAED       TAVYYCAKDR       100
                                             LVAPGTFDYW GQGALVTVSS ASTKGPSVFP                  LAPSSKSTSG       GTAALGCLVK       150
                                             DYFPEPVTVS WNSGALTSGV HTFPAVLQSS                  GLYSLSSVVT       VPSSSLGTQT       200
                                             YICNVNHKPS NTKVDKKVEP KSCDKTHTCP                  PCPAPELLGG       PSVFLFPPKP       250
                                             KDTLMISRTP EVTCVVVDVS HEDPEVKFNW                  YVDGVEVHNA       KTKPREEQYN       300
                                             STYRVVSVLT VLHQDWLNGK EYKCKVSNKA                  LPAPIEKTIS       KAKGQPREPQ       350
                                             VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI                  AVEWESNGQP       ENNYKTTPPV       400
                                             LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV                  MHEALHNHYT       QKSLSLSPG        449

                                             Light chain / Chaîne légère / Cadena ligera
                                             DIQMTQSPSS LSASVGDRVT ITCRASQGIS                  SWLAWYQQKP       EKAPKSLIYA 50
                                             ASSLQSGVPS RFSGSGSGTD FTLTISSLQP                  EDFATYYCQQ       YNSYPYTFGQ 100
                                             GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                                             DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                                             LSSPVTKSFN RGEC                                                               214

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H 22-96        147-203       264-324  370-428
                                                       22''-96'' 147''-203'' 264''-324'' 370''-428''
                                             Intra-L 23'-88'      134'-194'
                                                      23'''-88''' 134'''-194'''
                                             Inter-H-L 223-214' 223''-214'''
                                             Inter-H-H 229-229'' 232-232''

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             300, 300''




                                                                                                                                               79
Recommended INN: List 65                                     WHO Drug Information, Vol. 25, No. 1, 2011


 pegdinetanibum #
                                                                                                        th
 pegdinetanib              94 residues protein derived from human fibronectin 10 type III
                           domain, pegylated:
                           glycyl[1438-L-arginine(D>R),1439-L-histidine(A>H),1441-L-
                           histidine(A>H),1442-L-phenylalanine(V>F),1443-L-
                           proline(T>P),1444-L-threonine(V>T),1467-L-leucine(G>L),1468-L-
                           glutamine(S>Q),1469-L-proline(K>P),1470-L-proline(S>P),1492-L-
                           aspartic acid(G>D),1493-glycine(R>G),1494-L-arginine(G>R),1495-
                           L-asparagine(D>N),1496-glycine(S>G),1497-L-arginine(P>R),1498-L-
                           leucine(A>L),1499-L-leucine(S>L),1501-L-isoleucine(K>I),1515-S-
                           [(3RS)-1-(1-{[α-methylpoly(oxyethylene)]carbamoyl}-3-[({[α-
                           methylpoly(oxyethylene)]carbamoyl}oxy)methyl]-8,13-dioxo-
                           1,4-dioxa-9,12-diazapentadecan-15-yl)-2,5-dioxopyrrolidin-3-yl]-
                           L-cysteine(S>C)]human fibronectin-(1424-1516)-peptide

                                                                              ème
 pegdinétanib              protéine de 94 résidus derivée du 10    domaine de type III de la
                           fibronectine humaine pégylée :
                           glycyl[1438-L-arginine(D>R),1439-L-histidine(A>H),1441-L-
                           histidine(A>H),1442-L-phénylalanine(V>F),1443-L-
                           proline(T>P),1444-L-thréonine(V>T),1467-L-leucine(G>L),1468-L-
                           glutamine(S>Q),1469-L-proline(K>P),1470-L-proline(S>P),1492-
                           acide L-aspartique(G>D),1493-glycine(R>G),1494-L-
                           arginine(G>R),1495-L-asparagine(D>N),1496-glycine(S>G),1497-L-
                           arginine(P>R),1498-L-leucine(A>L),1499-L-leucine(S>L),1501-L-
                           isoleucine(K>I),1515-S-[(3RS)-1-(1-{[α-
                           méthylpoly(oxyéthylène)]carbamoyl}-3-[({[α-
                           méthylpoly(oxyéthylène)]carbamoyl}oxy)méthyl]-8,13-dioxo-
                           1,4-dioxa-9,12-diazapentadécan-15-yl)-2,5-dioxopyrrolidin-3-yl]-
                           L-cystéine(S>C)]fibronectine humaine-(1424-1516)-peptide

 pegdinetanib              proteína de 94 residuos derivada del décimo dominio de tipo III de la
                           fibronectina humana pegilada :
                           glicil[1438-L-arginina(D>R),1439-L-histidina(A>H),1441-L-
                           histidina(A>H),1442-L-fenilalanina(V>F),1443-L-prolina(T>P),1444-L-
                           treonina(V>T),1467-L-leucina(G>L),1468-L-glutamina(S>Q),1469-L-
                           prolina(K>P),1470-L-prolina(S>P),1492-ácido L-
                           aspártico(G>D),1493-glicina(R>G),1494-L-arginina(G>R),1495-L-
                           asparagina(D>N),1496-glicina(S>G),1497-L-arginina(P>R),1498-L-
                           leucina(A>L),1499-L-leucina(S>L),1501-L-isoleucina(K>I),1515-S-
                           [(3RS)-1-(1-{[α-metilpoli(oxietileno)]carbamoil}-3-[({[α-
                           metilpoli(oxietileno)]carbamoil}oxi)metil]-8,13-dioxo-1,4-dioxa-
                           9,12-diazapentadecan-15-il)-2,5-dioxopirrolidin-3-il]-
                           L-cisteína(S>C)]fibronectina humana-(1424-1516)-péptido

                                                   GEVVAATP TSLLISWRHP HFPTRYYRIT 1450
                           YGETGGNSPV QEFTVPLQPP TATISGLKPG VDYTITVYAV TDGRNGRLLS 1500
                           IPISINYRTE IDKPCQ                                      1516

                           Modified residue / Résidu modifié / Residuo modificado
                                                                                       H
                                    C                                         O        N
                                   1515
                            pegylated cystein                     H
                            cystéine pégylée    H3C               N       O
                            cisteína pegilada          O                                       NH            O
                                                                  n
                                                                      O                                          H
                                                                                  O        O            N
                                                                  H                                                  S
                                                H3C               N       O                                      H
                                                       O                                            O
                                                                  n
                                                                      O               n # 450                    N
                                                                                                                 H
                                                                                                                         O




80
WHO Drug Information, Vol. 25, No. 1, 2011                                                             Recommended INN: List 65


 peginesatidum #
 peginesatide                                pegylated erythropoietin receptor agonist,
                                               6.21  6.21'  2   6
                                             N ,N -{[(N ,N -bis{[ω-methoxypoly(oxyethylene)]carbonyl}-
                                             L-lysyl-β-alanyl)imino]bis(methylenecarbonyl)}bis[N-
                                             acetylglycylglycyl-L-leucyl-L-tyrosyl-L-alanyl-L-cysteinyl-L-histidyl-
                                             L-methionylglycyl-L-prolyl-L-isoleucyl-L-threonyl-3-(naphthalen-1-yl)-
                                             L-alanyl-L-valyl-L-cysteinyl-L-glutaminyl-L-prolyl-L-leucyl-L-arginyl-
                                             N-methylglycyl-L-lysinamide] (6→15:6'→15')-bisdisulfure cyclic

 péginésatide                                agoniste du récepteur de l'érythropoïétine, pégylé
                                                                                          6.21 6.21'  2   6
                                             (6→15:6'→15')-bisdisulfure cyclique du N ,N -{[(N ,N -bis{[ω-
                                             méthoxypoly(oxyéthylène)]carbonyl}-L-lysyl-
                                             β-alanyl)imino]bis(méthylènecarbonyl)}bis[acétylglycylglycyl-L-leucyl-
                                             L-tyrosyl-L-alanyl-L-cystéinyl-L-histidyl-L-méthionylglycyl-L-prolyl-
                                             L-isoleucyl-L-thréonyl-3-(naphtalén-1-yl)-L-alanyl-L-valyl-L-cystéinyl-
                                             L-glutaminyl-L-prolyl-L-leucyl-L-arginyl-N-méthylglycyl-L-lysinamide]

 peginesatida                                agonista del receptor de la eritropoyetina, pegilado
                                                                                             6.21   6.21'  2   6
                                             (6→15:6'→15')-bisdisulfuro cíclico del N ,N -{[(N ,N -bis{[ω-
                                             metoxipoli(oxietileno)]carbonil}-L-lisil-
                                                                                              6   15
                                             β-alanil)imino]bis(metilenocarbonil)}bis{S ,S -ciclo[N-acetilglicilglicil-
                                             L-leucil-L-tirosil-L-alanil-L-cisteinil-L-histidil-L-metionilglicil-L-prolil-
                                             L-isoleucil-L-treonil-3-(naftalen-1-il)-L-alanil-L-valil-L-cisteinil-
                                             L-glutaminil-L-prolil-L-leucil-L-arginil-N-metilglicil-L-lisinamida]

                                             C231H350N62O58S6[C2H4O]n

                                                      O
                                                                Gly Gly Leu Tyr Ala Cys His Met Gly
                                                  H3C
                                                    Pro Ile Thr Nal Val Cys Gln Pro Leu Arg Sar Lys NH2
                                                      10                                                            20
                                                                                  O                                       N6

                                                                  O
                                                           H3C                O       N                                         O
                                                                                  a   H
                                                                                                                         N
                                             n = a + b # 900                              O
                                                                                              H                                 O
                                                                          O                                NH       O
                                                                  H3C                 O       N
                                                                                          b   H
                                                      O                                               O
                                                                Gly Gly Leu Tyr Ala Cys His Met Gly
                                                  H3C                                          N6
                                                    Pro Ile Thr Nal Val Cys Gln Pro Leu Arg Sar Lys NH2
                                                      10'                                                           20'



                                             3-(naphthalen-1-
                                             yl)-L-alanyl
                                                                                                     Sar        =
                                                                                                                          N
                                                                          H
                                                                                                  N-methylglycyl          CH3   O
                                                Nal         =         N
                                                                      H
                                                                          O




                                                                                                                                    81
Recommended INN: List 65                                   WHO Drug Information, Vol. 25, No. 1, 2011


 ponesimodum
 ponesimod                 (2Z,5Z)-5-{3-chloro-4-[(2R)-2,3-
                           dihydroxypropoxy]phenylmethylidene}-3-(2-methylphenyl)-
                           2-(propylimino)-1,3-thiazolidin-4-one

 ponésimod                 (2Z,5Z)-5-{3-chloro-4-[(2R)-2,3-
                           dihydroxypropoxy]phénylméthylidène}-3-(2-méthylphényl)-
                           2-(propylimino)-1,3-thiazolidin-4-one

 ponesimod                 (2Z,5Z)-5-{3-cloro-4-[(2R)-2,3-dihidroxipropoxi]fenilmetilideno}-
                           3-(2-metilfenil)-2-(propilimino)-1,3-tiazolidin-4-ona

                           C23H25CIN2O4S

                                        O
                                                               Cl
                                    N
                              CH3           S
                                                               O           OH
                                    N
                                                                    H OH

                                                CH3




 rezatomidinum
 rezatomidine              4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1,3-dihydro-2H-imidazol-
                           2-thione

 rézatomidine              4-[(1S)-1-(2,3-diméthylphényl)éthyl]-1,3-dihydro-2H-imidazole-
                           2-thione

 rezatomidina              4-[(1S)-1-(2,3-dimetilfenil)etil]-1,3-dihidro-2H-imidazol-2-tiona

                           C13H16N2S

                                                       H
                                                       N
                                                           S
                           H3C                         N
                                                       H
                                    CH3 H        CH3




 roledumabum #
 roledumab                 immunoglobulin G1-kappa, anti-[Homo sapiens RHD (Rhesus blood
                           group D antigen, RhD, CD240D)], Homo sapiens monoclonal
                           antibody;
                           gamma1 heavy chain (1-456) [Homo sapiens VH (IGHV3-30*01
                           (86.70%) -(IGHD)-IGHJ3*02) [8.8.19] (1-126) -IGHG1*01 (127-456)],
                           (229-214')-disulfide with kappa light chain (1'-214') [Homo sapiens V-
                           KAPPA (IGKV1-8*01 (89.50%) -IGKJ1*01 K123>R, K127>T) [6.3.9]
                           (1'-107') -IGKC*01 (108'-214')]; (235-235'':238-238'')-bisdisulfide
                           dimer




82
WHO Drug Information, Vol. 25, No. 1, 2011                                                             Recommended INN: List 65




 rolédumab                                   immunoglobuline G1-kappa, anti-[Homo sapiens RHD (antigène
                                             groupe sanguin Rhésus D, RhD, CD240D)], Homo sapiens anticorps
                                             monoclonal;
                                             chaîne lourde gamma1 (1-456) [Homo sapiens VH (IGHV3-30*01
                                             (86.70%) -(IGHD)-IGHJ3*02) [8.8.19] (1-126) -IGHG1*01 (127-456)],
                                             (229-214')-disulfure avec la chaîne légère kappa (1'-214') [Homo
                                             sapiens V-KAPPA (IGKV1-8*01 (89.50%) -IGKJ1*01 K123>R,
                                             K127>T) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (235-
                                             235'':238-238'')-bisdisulfure

 roledumab                                   inmunoglobulina G1-kappa, anti-[Homo sapiens RHD (antígeno
                                             sanguíneo D Rhesus, RhD, CD240D)], anticuerpo monoclonal de
                                             Homo sapiens ;
                                             cadena pesada gamma1 (1-456) [Homo sapiens VH (IGHV3-30*01
                                             (86.70%) -(IGHD)-IGHJ3*02) [8.8.19] (1-126) -IGHG1*01 (127-456)],
                                             (229-214')-disulfuro con la cadena ligera kappa (1'-214') [Homo
                                             sapiens V-KAPPA (IGKV1-8*01 (89.50%) -IGKJ1*01 K123>R,
                                             K127>T) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (235-
                                             235'':238-238'')-bisdisulfuro

                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             QVQLVESGGG VVQPGRSLRL SCTASGFTFK                  NYAMHWVRQA       PAKGLEWVAT        50
                                             ISYDGRNIQY ADSVKGRFTF SRDNSQDTLY                  LQLNSLRPED       TAVYYCARPV       100
                                             RSRWLQLGLE DAFHIWGQGT MVTVSSASTK                  GPSVFPLAPS       SKSTSGGTAA       150
                                             LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP                  AVLQSSGLYS       LSSVVTVPSS       200
                                             SLGTQTYICN VNHKPSNTKV DKKVEPKSCD                  KTHTCPPCPA       PELLGGPSVF       250
                                             LFPPKPKDTL MISRTPEVTC VVVDVSHEDP                  EVKFNWYVDG       VEVHNAKTKP       300
                                             REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC                  KVSNKALPAP       IEKTISKAKG       350
                                             QPREPQVYTL PPSRDELTKN QVSLTCLVKG                  FYPSDIAVEW       ESNGQPENNY       400
                                             KTTPPVLDSD GSFFLYSKLT VDKSRWQQGN                  VFSCSVMHEA       LHNHYTQKSL       450
                                             SLSPGK                                                                              456

                                             Light chain / Chaîne légère / Cadena ligera
                                             AIRMTQSPSS FSASTGDRVT ITCRASQDIR                  NYVAWYQQKS       GKAPKFLIYA 50
                                             ASTLQSGVPS RFSGSGSGTD FTLTINSLQS                  EDFATYYCQQ       YYNSPPTFGQ 100
                                             GTRVEITRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                                             DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                                             LSSPVTKSFN RGEC                                                               214

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H 22-96        153-209       270-330  376-434
                                                      22''-96'' 153''-209'' 270''-330'' 376''-434''
                                             Intra-L 23'-88'      134'-194'
                                                      23'''-88''' 134'''-194'''
                                             Inter-H-L 229-214' 229''-214'''
                                             Inter-H-H 235-235'' 238-238''

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             306, 306''



 ruxolitinibum
 ruxolitinib                                 (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-
                                             1-yl]propanenitrile

 ruxolitinib                                 (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-
                                             1-yl]propanenitrile

 ruxolitinib                                 (3R)-3-ciclopentil-3-[4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-
                                             1-il]propanonitrilo




                                                                                                                                               83
Recommended INN: List 65                           WHO Drug Information, Vol. 25, No. 1, 2011




                           C17H18N6


                                               H
                                  N                 CN
                            N               N
                                           N
                           HN




 samalizumabum #
 samalizumab               immunoglobulin G2-kappa, anti-[Homo sapiens CD200 (OX-2)],
                           humanized monoclonal antibody;
                           gamma2 heavy chain (1-442) [humanized VH (Homo sapiens
                           IGHV1-69*01 (73.50%) -(IGHD)-IGHJ4*01 L123>T, V124>L) [8.8.10]
                           (1-117) -Homo sapiens IGHG2*01 CH1-hinge-CH2 1.6-1.1 (118-
                           232)- IGHG4*01 CH2 1-125, CH3 1-129 K130>del (233-442)], (131-
                           214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA
                           (Homo sapiens IGKV1-33*01 (81.10%) -IGKJ2*01 Q120>G) [6.3.9]
                           (1'-107') -Homo sapiens IGKC*01 (108'-214')]; (219-219":220-
                           220":223-223":226-226")-tetrakisdisulfide dimer

 samalizumab               immunoglobuline G2-kappa, anti-[Homo sapiens CD200 (OX-2)],
                           anticorps monoclonal humanisé;
                           chaîne lourde gamma2 (1-442) [VH humanisé (Homo sapiens
                           IGHV1-69*01 (73.50%) -(IGHD)-IGHJ4*01 L123>T, V124>L) [8.8.10]
                           (1-117) -Homo sapiens IGHG2*01 CH1-charnière-CH2 1.6-1.1 (118-
                           232)- IGHG4*01 CH2 1-125, CH3 1-129 K130>del (233-442)], (131-
                           214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA
                           humanisé (Homo sapiens IGKV1-33*01 (81.10%) -IGKJ2*01
                           Q120>G) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')];
                           dimère (219-219":220-220":223-223":226-226")-tétrakisdisulfure

 samalizumab               inmunoglobulina G2-kappa, anti-[Homo sapiens CD200 (OX-2)],
                           anticuerpo monoclonal humanizado; cadena pesado gamma2 (1-
                           442) [humanizado VH (Homo sapiens IGHV1-69*01 (73.50%) -
                           (IGHD)-IGHJ4*01 L123>T, V124>L) [8.8.10] (1-117) -Homo sapiens
                           IGHG2*01 CH1-bisagra-CH2 1.6-1.1 (118-232)- IGHG4*01 CH2 1-
                           125, CH3 1-129 K130>del (233-442)], (131-214')-disulfuro con la
                           cadena ligera kappa (1'-214') [V-KAPPA humanizada(Homo sapiens
                           IGKV1-33*01 (81.10%) -IGKJ2*01 Q120>G) [6.3.9] (1'-107') -Homo
                           sapiens IGKC*01 (108'-214')]; dímero (219-219":220-220":223-
                           223":226-226")-tetrakisdisulfuro




84
WHO Drug Information, Vol. 25, No. 1, 2011                                                             Recommended INN: List 65




                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             QVQLQQSGSE LKKPGASVKI SCKASGYSFT                  DYIILWVRQN       PGKGLEWIGH        50
                                             IDPYYGSSNY NLKFKGRVTI TADQSTTTAY                  MELSSLRSED       TAVYYCGRSK       100
                                             RDYFDYWGQG TTLTVSSAST KGPSVFPLAP                  CSRSTSESTA       ALGCLVKDYF       150
                                             PEPVTVSWNS GALTSGVHTF PAVLQSSGLY                  SLSSVVTVPS       SNFGTQTYTC       200
                                             NVDHKPSNTK VDKTVERKCC VECPPCPAPP                  VAGPSVFLFP       PKPKDTLMIS       250
                                             RTPEVTCVVV DVSQEDPEVQ FNWYVDGVEV                  HNAKTKPREE       QFNSTYRVVS       300
                                             VLTVLHQDWL NGKEYKCKVS NKGLPSSIEK                  TISKAKGQPR       EPQVYTLPPS       350
                                             QEEMTKNQVS LTCLVKGFYP SDIAVEWESN                  GQPENNYKTT       PPVLDSDGSF       400
                                             FLYSRLTVDK SRWQEGNVFS CSVMHEALHN                  HYTQKSLSLS       LG               442

                                             Light chain / Chaîne légère / Cadena ligera
                                             DIQMTQSPSS LSASIGDRVT ITCKASQDIN                  SYLSWFQQKP       GKAPKLLIYR 50
                                             ANRLVDGVPS RFSGSGSGTD YTLTISSLQP                  EDFAVYYCLQ       YDEFPYTFGG 100
                                             GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                                             DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                                             LSSPVTKSFN RGEC                                                               214

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H 22-96        144-200       257-317  363-421
                                                       22''-96'' 144''-200'' 257''-317'' 363''-421''
                                             Intra-L 23'-88'      134'-194'
                                                      23'''-88''' 134'''-194'''
                                             Inter-H-L 131-214' 131''-214'''
                                             Inter-H-H 219-219'' 220-220'' 223-223'' 226-226''

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             293, 293''



 simenepagum
 simenepag                                   5-({[(2R)-1-{4-[(1S)-1-hydroxyhexyl]phenyl}-5-oxopyrrolidin-
                                             2-yl]methoxy}methyl)thiophene-2-carboxylic acid

 siménépag                                   acide 5-({[(2R)-1-{4-[(1S)-1-hydroxyhexyl]phényl}-5-oxopyrrolidin-
                                             2-yl]méthoxy}méthyl)thiophène-2-carboxylique

 simenepag                                   ácido 5-({[(2R)-1-{4-[(1S)-1-hidroxihexil]fenil}-5-oxopirrolidin-
                                             2-il]metoxi}metil)tiofeno-2- carboxílico

                                             C23H29NO5S

                                                   H
                                                                       S       CO2H
                                                           O
                                                      N

                                              O                                         CH3

                                                                 H OH



 somatropinum pegolum #
                                              5.141
 somatropin pegol                            N    -[(2E)-({2-[({2,3-bis[ω-methoxypoly(oxyethylene)]propoxy}=
                                             carbonyl)amino]ethoxy}imino)ethyl]human somatotropin (growth
                                             hormone)
                                              5.141
 somatropine pégol                           N    -[(2E)-({2-[({2,3-bis[ω-méthoxypoly(oxyéthylène)]propoxy}=
                                             carbonyl)amino]éthoxy}imino)éthyl]somatotropine humaine (hormone
                                             de croissance)
                                              5.141
 somatropina pegol                           N    -[(2E)-({2-[({2,3-bis[ω-metoxipoli(oxietileno)]propoxi}carbonil)=
                                             amino]etoxi}imino)etil]somatotropina humana (hormona de
                                             crecimiento)




                                                                                                                                               85
Recommended INN: List 65                                      WHO Drug Information, Vol. 25, No. 1, 2011




                           FPTIPLSRLF          DNAMLRAHRL     HQLAFDTYQE        FEEAYIPKEQ    KYSFLQNPQT 50
                           SLCFSESIPT          PSNREETQQK     SNLELLRISL        LLIQSWLEPV    QFLRSVFANS 100
                           LVYGASDSNV          YDLLKDLEEG     IQTLMGRLED        GSPRTGQIFK    QTYSKFDTNS 150
                           HNDDALLKNY          GLLYCFRKDM     DKVETFLRIV        QCRSVEGSCG    F          191

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           53-165 182-189

                           Modified residue / Résidu modifié / Residuo modificado
                                                                                      H
                                                       H3 C            O      O       N          N
                                                              O                              O            NH
                                                                       n
                                    Q                         O                   O                            O
                                 Gln(141)              H3 C            O
                                                                       n
                                                                                                      H
                                                                           n # 480
                                                                                                     N
                                                                                                     H
                                                                                                           O



 taprenepagum
 taprenepag                2-{3-[(N-{[4-(1H-pyrazol-1-yl)phenyl]methyl}pyridine-
                           3-sulfonamido)methyl]phenoxy}acetic acid

 taprénépag                acide 2-{3-[(N-{[4-(1H-pyrazol-1-yl)phényl]méthyl}pyridine-
                           3-sulfonamido)méthyl]phénoxy}acétique

 taprenepag                ácido 2-{3-[(N-{[4-(1H-pirazol-1-il)fenil]metil}piridina-
                           3-sulfonamido)metil]fenoxi}acético

                           C24H22N4O5S

                                            O          CO2H




                                       N
                                       S       O                  N
                           N                                  N
                                           O




 tedalinabum
 tedalinab                 (4S,7R)-N-tert-butyl-1-(2,4-difluorophenyl)-4,5,6,7-tetrahydro-
                           1H-4,7-methanoindazole-3-carboxamide

 tédalinab                 (4S,7R)-N-tert-butyl-1-(2,4-difluorophényl)-4,5,6,7-tétrahydro-
                           1H-4,7-méthanoindazole-3-carboxamide

 tedalinab                 (4S,7R)-N-terc-butil-1-(2,4-difluorofenil)-4,5,6,7-tetrahidro-
                           1H-4,7-metanoindazol-3-carboxamida

                           C19H21F2N3O

                           F
                                                        O H3C     CH3
                                                   N
                                            N                 N       CH3
                                                              H
                                   F
                                       H                  H




86
WHO Drug Information, Vol. 25, No. 1, 2011                                                     Recommended INN: List 65


 tegobuvirum
 tegobuvir                                   5-({6-[2,4-bis(trifluoromethyl)phenyl]pyridazin-3-yl}methyl)-
                                             2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine

 tégobuvir                                   5-({6-[2,4-bis(trifluorométhyl)phényl]pyridazin-3-yl}méthyl)-
                                             2-(2-fluorophényl)-5H-imidazo[4,5-c]pyridine

 tegobuvir                                   5-({6-[2,4-bis(trifluorometil)fenil]piridazin-3-il}metil)-2-(2-fluorofenil)-
                                             5H-imidazo[4,5-c]piridina

                                             C25H14F7N5

                                             F3C
                                                                                           F
                                                                N                      N
                                                                    N
                                                        CF3                 N
                                                                                       N



 telapristonum
 telapristone                                11β-[4-(dimethylamino)phenyl]-17-hydroxy-21-methoxy-
                                             19-norpregna-4,9-diene-3,20-dione

 télapristone                                11β-[4-(diméthylamino)phényl]-17-hydroxy-21-méthoxy-
                                             19-norprégna-4,9-diène-3,20-dione

 telapristona                                11β-[4-(dimetilamino)fenil]-17-hidroxi-21-metoxi-19-norpregna-
                                             4,9-dieno-3,20-diona

                                             C29H37NO4

                                                    CH3
                                                                                   O CH3
                                                    N                       O
                                             H3C
                                                                H       CH3
                                                                                OH
                                                                    H

                                                                        H
                                                   O



 temanogrelum
 temanogrel                                  3-methoxy-N-{3-(1-methyl-1H-pyrazol-5-yl)-4-[2-(morpholin-
                                             4-yl)ethoxy]phenyl}benzamide

 témanogrel                                  3-méthoxy-N-{3-(1-méthyl-1H-pyrazol-5-yl)-4-[2-(morpholin-
                                             4-yl)éthoxy]phényl}benzamide

 temanogrel                                  N-{3-(1-metil-1H-pirazol-5-il)-4-[2-(morfolin-4-il)etoxi]fenil}-
                                             3-metoxibenzamida

                                             C24H28N4O4

                                                                            H3 C
                                                                                   N N
                                                                    H
                                                                    N
                                             H3CO                                                O
                                                               O                           N
                                                                                   O




                                                                                                                            87
Recommended INN: List 65                                    WHO Drug Information, Vol. 25, No. 1, 2011




 tiprelestatum
 tiprelestat               human elafin (elastase-specific inhibitor, skin-derived
                           antileukoproteinase, peptidase inhibitor 3)

 tiprélestat               élafine humaine (inhibiteur spécifique de l'élastase,
                           antileukoprotéinase dérivé de la peau, inhibiteur 3 de peptidase)

 tiprelestat               elafina humana (inhibidor específico de la elastasa,
                           antileukoproteinasa derivada de la piel, inhibidor 3 de peptidasa)

                           C254H416N72O75S10

                           AQEPVKGPVS         TKPGSCPIIL       IRCAMLNPPN         RCLKDTDCPG        IKKCCEGSCG         50
                           MACFVPQ                                                                                     57

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           16-45 23-49 32-44 38-53



 tivantinibum
 tivantinib                (3R,4R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-
                           3-yl)pyrrolidine-2,5-dione

 tivantinib                (3R,4R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinoléin-1-yl)-4-(1H-indol-
                           3-yl)pyrrolidine-2,5-dione

 tivantinib                (3R,4R)-3-(5,6-dihidro-4H-pirrolo[3,2,1-ij]quinolein-1-il)-4-(1H-indol-
                           3-il)pirrolidina-2,5-diona

                           C23H19N3O2

                                          H
                                  O       N       O


                           HN           H H             N




 tofogliflozinum
 tofogliflozin             (1S,3'R,4'S,5'S,6'R)-6-[(4-ethylphenyl)methyl]-6'-(hydroxymethyl)-
                           3',4',5',6'-tetrahydro-3H-spiro[2-benzofuran-1,2'-pyran]-3',4',5'-triol

 tofogliflozine            (1S,3'R,4'S,5'S,6'R)-6-[(4-éthylphényl)méthyl]-6'-(hydroxyméthyl)-
                           3',4',5',6'-tétrahydro-3H-spiro[2-benzofuran-1,2'-pyran]-3',4',5'-triol

 tofogliflozina            (1S,3'R,4'S,5'S,6'R)-6-[(4-etilfenil)metil]-6'-(hidroximetil)-3',4',5',6'-
                           tetrahidro-3H-espiro[2-benzofurano-1,2'-pirano]-3',4',5'-triol




88
WHO Drug Information, Vol. 25, No. 1, 2011                                           Recommended INN: List 65




                                             C22H26O6

                                                                         CH3




                                             HO

                                                        O
                                                  OH
                                             HO              O

                                                        OH



 trastuzumabum emtansinum #
 trastuzumab emtansine                       immunoglobulin G1-kappa, anti-[Homo sapiens ERBB2 (epidermal
                                             growth factor receptor 2, HER-2, p185c-erbB2, NEU, EGFR2)],
                                             humanized monoclonal antibody conjugated to maytansinoid DM1;
                                             gamma1 heavy chain (1-449) [humanized VH (Homo sapiens
                                             IGHV3-66*01 (81.60%) -(IGHD)-IGHJ6*01 T123>L) [8.8.13] (1-120) -
                                             Homo sapiens IGHG1*03 (121-449) CH1 R120>K], (223-214')-
                                             disulfide with kappa light chain (1'-214') [humanized V-KAPPA
                                             (Homo sapiens IGKV1-39*01 (86.30%) -IGKJ1*01) [6.3.9] (1'-107') -
                                             Homo sapiens IGKC*01 (108'-214')]; (229-229":232-232")-
                                             bisdisulfide dimer; conjugated, on an average of 3 to 4 lysyl, to
                                             maytansinoid DM1 via a succinimidyl-4-(N-maleimidomethyl)
                                             cyclohexane-1-carboxylate (SMCC) linker
                                             For the emtansine part, please refer to the document "INN for
                                             pharmaceutical substances: Names for radicals, groups and
                                             others"*.

 trastuzumab emtansine                       immunoglobuline G1-kappa, anti-[Homo sapiens ERBB2 (récepteur
                                             2 du facteur de croissance épidermique, HER-2, p185c-erbB2, NEU,
                                             EGFR2)]], anticorps monoclonal humanisé conjugué au
                                             maytansinoïde DM1;
                                             chaîne lourde gamma1 (1-449) [VH humanisé (Homo sapiens
                                             IGHV3-66*01 (81.60%) -(IGHD)-IGHJ6*01 T123>L) [8.8.13] (1-120) -
                                             Homo sapiens IGHG1*03 (121-449) CH1 R120>K], (223-214')-
                                             disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé
                                             (Homo sapiens IGKV1-39*01 (86.30%) -IGKJ1*01) [6.3.9] (1'-107') -
                                             Homo sapiens IGKC*01 (108'-214')]; dimère (229-229":232-232")-
                                             bisdisulfure; conjugué, sur 3 à 4 lysyl en moyenne, au
                                             maytansinoïde DM1 via un linker succinimidyl-4-(N-
                                             maléimidométhyl) cyclohexane-1-carboxylate (SMCC)
                                             Pour la partie emtasine, veuillez vous référer au document "INN for
                                             pharmaceutical substances: Names for radicals, groups and
                                             others"*.




                                                                                                               89
Recommended INN: List 65                                     WHO Drug Information, Vol. 25, No. 1, 2011




 trastuzumab emtansina     inmunoglobulina G1-kappa, anti-[Homo sapiens ERBB2 (receptor 2
                           del factor de crecimiento epidérmico, HER-2, p185c-erbB2, NEU,
                           EGFR2)]], anticuerpo monoclonal humanizado conjugado con
                           maitansinoide DM1;
                           cadena pesada gamma1 (1-449) [VH humanizado (Homo sapiens
                           IGHV3-66*01 (81.60%) -(IGHD)-IGHJ6*01 T123>L) [8.8.13] (1-120) -
                           Homo sapiens IGHG1*03 (121-449) CH1 R120>K], (223-214')-
                           disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado
                           (Homo sapiens IGKV1-39*01 (86.30%) -IGKJ1*01) [6.3.9] (1'-107') -
                           Homo sapiens IGKC*01 (108'-214')]; dimero (229-229":232-232")-
                           bisdisulfuro; conjugado, en 3 a 4 residuos lisil por término medio,
                           con el maitansinoide DM1 mediante un conector succinimidil-4-(N-
                           maleimidometil) ciclohexano-1-carboxilato (SMCC)
                           Por la parte emtansina, por favor, vaya al documento "INN for
                           pharmaceutical substances: Names for radicals, groups & others"*.

                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLVESGGG LVQPGGSLRL SCAASGFNIK                  DTYIHWVRQA       PGKGLEWVAR        50
                           IYPTNGYTRY ADSVKGRFTI SADTSKNTAY                  LQMNSLRAED       TAVYYCSRWG       100
                           GDGFYAMDYW GQGTLVTVSS ASTKGPSVFP                  LAPSSKSTSG       GTAALGCLVK       150
                           DYFPEPVTVS WNSGALTSGV HTFPAVLQSS                  GLYSLSSVVT       VPSSSLGTQT       200
                           YICNVNHKPS NTKVDKKVEP KSCDKTHTCP                  PCPAPELLGG       PSVFLFPPKP       250
                           KDTLMISRTP EVTCVVVDVS HEDPEVKFNW                  YVDGVEVHNA       KTKPREEQYN       300
                           STYRVVSVLT VLHQDWLNGK EYKCKVSNKA                  LPAPIEKTIS       KAKGQPREPQ       350
                           VYTLPPSREE MTKNQVSLTC LVKGFYPSDI                  AVEWESNGQP       ENNYKTTPPV       400
                           LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV                  MHEALHNHYT       QKSLSLSPG        449

                           Light chain / Chaîne légère / Cadena ligera
                           DIQMTQSPSS LSASVGDRVT ITCRASQDVN                  TAVAWYQQKP       GKAPKLLIYS 50
                           ASFLYSGVPS RFSGSRSGTD FTLTISSLQP                  EDFATYYCQQ       HYTTPPTFGQ 100
                           GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                           DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                           LSSPVTKSFN RGEC                                                               214

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96        147-203       264-324  370-428
                                     22''-96'' 147''-203'' 264''-324'' 370''-428''
                           Intra-L 23'-88' 134'-194'
                                    23'''-88''' 134'''-194'''
                           Inter-H-L 223-214' 223''-214'''
                           Inter-H-H 229-229'' 232-232''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           300, 300''



 ulimorelinum
 ulimorelin                (2R,5S,8R,11R)-5-cyclopropyl-11-[(4-fluorophenyl)methyl]-
                           2,7,8-trimethyl-2,3,4,5,7,8,10,11,13,14,15,16-dodecahydro-
                           6H-1,4,7,10,13-benzoxatetraazacyclooctadecine-6,9,12-trione

 ulimoréline               (2R,5S,8R,11R)-5-cyclopropyl-11-[(4-fluorophényl)méthyl]-
                           2,7,8-triméthyl-2,3,4,5,7,8,10,11,13,14,15,16-dodécahydro-
                           6H-1,4,7,10,13-benzoxatétraazacyclooctadécine-6,9,12-trione

 ulimorelina               (2R,5S,8R,11R)-5-ciclopropil-11-[(4-fluorofenil)metil]-2,7,8-trimetil-
                           2,3,4,5,7,8,10,11,13,14,15,16-dodecahidro-6H-1,4,7,10,13-
                           benzoxatetraazaciclooctadecino-6,9,12(5H)-triona




90
WHO Drug Information, Vol. 25, No. 1, 2011                                                     Recommended INN: List 65


                                             C30H39FN4O4


                                                                        H
                                                  H3C
                                                                             O
                                                  H             N
                                                                H                H
                                                        O                N
                                                                H 3C                 CH3

                                                                        HN         O
                                                                H
                                                                N            H
                                                                                           F
                                                                    O



 umifenovirum
 umifenovir                                  ethyl 6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-
                                             2-[(phenylsulfanyl)methyl]-1H-indole-3-carboxylate

 umifénovir                                  6-bromo-4-[(diméthylamino)méthyl]-5-hydroxy-1-méthyl-
                                             2-[(phénylsulfanyl)méthyl]-1H-indole-3-carboxylate d'éthyle

 umifenovir                                  6-bromo-4-[(dimetilamino)metil]-5-hidroxi-1-metil-
                                             2-[(fenilsulfanil)metil]-1H-indol-3-carboxilato de etilo

                                             C22H25BrN2O3S

                                                      Br

                                                                         CH3
                                                HO                  N
                                             H3 C
                                                                               S
                                                  N
                                             H3 C
                                                            O
                                                                    O
                                                                             CH3



 umirolimusum
 umirolimus                                  (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-
                                             3-{(1R)-2-[(1S,3R,4R)-4-(2-ethoxyethoxy)-3-méthoxycyclohexyl]-
                                             1-methylehyl}-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-
                                             hexamethyl-3,4,9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34ª-
                                             octadecahydro-23,27-epoxy-5H-pyrido[2,1-
                                             c][1,4]oxazacyclohentriacontine-1,5,11,28,29(6H,31H)-pentone

 umirolimus                                  (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-
                                             3-{(1R)-2-[(1S,3R,4R)-4-(2-ethoxyethoxy)-3-méthoxycyclohexyl]-
                                             1-methylehyl}-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-
                                             hexamethyl-3,4,9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34ª-
                                             octadecahydro-23,27-epoxy-5H-pyrido[2,1-
                                             c][1,4]oxazacyclohentriacontine-1,5,11,28,29(6H,31H)-pentone

 umirolimús                                  (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-
                                             3-{(1R)-2-[(1S,3R,4R)-4-(2-etoxietoxi)-3-metoxiciclohexil]-1-metiletil}-
                                             9,27-dihidroxi-10,21-dimetoxi-6,8,12,14,20,26-hexametil-
                                             3,4,9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34ª-octadecahidro-
                                             23,27-epoxi-5H-pirido[2,1-c][1,4]oxazaciclohentriacontina-
                                             1,5,11,28,29(6H,31H)-pentona




                                                                                                                     91
Recommended INN: List 65                                        WHO Drug Information, Vol. 25, No. 1, 2011


                           C55H87NO14

                                                      O     CH3
                                        O
                                    H
                                H
                           H3CO
                                                  H
                                                      CH3
                                        O             H O            H OH
                                    H         H
                                                                                   O
                                              O
                                                                       H
                                    N         O           H3C   H CH3      OCH3
                                                                 CH3
                                              OH H                         H3C H
                                                O                                       H
                                    O
                                                                                       CH3
                                        H                  H OCH3
                                        H3C

 uridini triacetas
 uridine triacetate        2',3',5'-tri-O-acetyluridine

 triacétate d'uridine      2',3',5'-tri-O-acétyluridine

 triacetato de uridina     2',3',5'-tri-O-acetiluridina

                           C15H18N2O9

                                                      O

                           O        CH3         HN

                               O            O         N
                                            O



                            H3C         O         O       CH3

                                    O                 O

 vaniprevirum
 vaniprevir                (5R,7S,10S)-10-tert-butyl-N-{(1R,2R)-1-[N-
                           (cyclopropanesulfonyl)carbamoyl]-2-ethylcyclopropyl}-15,15-
                           dimethyl-3,9,12-trioxo-6,7,9,10,11,12,14,15,16,17,18,19-
                           dodecahydro-1H,3H,5H-2,23:5,8-dimethano-4,13,2,8,11-
                           benzodioxatriazacyclohenicosine-7-carboxamide

 vaniprévir                (5R,7S,10S)-10-tert-butyl-N-{(1R,2R)-1-[N-
                           (cyclopropanesulfonyl)carbamoyl]-2-éthylcyclopropyl}-15,15-
                           diméthyl-3,9,12-trioxo-6,7,9,10,11,12,14,15,16,17,18,19-
                           dodécahydro-1H,3H,5H-2,23:5,8-diméthano-4,13,2,8,11-
                           benzodioxatriazacyclohénicosine-7-carboxamide

 vaniprevir                (5R,7S,10S)-10-terc-butil-N-{(1R,2R)-1-[N-
                           (ciclopropanosulfonil)carbamoil]-2-etilciclopropil} -15,15-dimetil-
                           3,9,12-trioxo-6,7,9,10,11,12,14,15,16,17,18,19-dodecahidro-
                           1H,3H,5H-2,23:5,8-dimetano-4,13,2,8,11-
                           benzodioxatriazaciclohenicosina-7-carboxamida




92
WHO Drug Information, Vol. 25, No. 1, 2011                                                             Recommended INN: List 65


                                             C38H55N5O9S




                                                                                   N       O
                                                                                   H
                                                                H3C                    O
                                             H3C                          CH3
                                                               H3C
                                             H3C                                                   O    O O
                                                               O H             N           H
                                                                                           N             S
                                                                     NH                                N
                                                                          O        H                   H
                                                               O                       O
                                                                                               H       CH3



 vemurafenibum
 vemurafenib                                 N-{3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-carbonyl]-
                                             2,4-difluorophenyl}propane-1-sulfonamide

 vémurafénib                                 N-{3-[5-(4-chlorophényl)-1H-pyrrolo[2,3-b]pyridin-3-carbonyl]-
                                             2,4-difluorophényl}propane-1-sulfonamide

 vemurafenib                                 N-{3-[5-(4-clorofenil)-1H-pirrolo[2,3-b]piridin-3-carbonil]-
                                             2,4-difluorofenil}propano-1-sulfonamida

                                             C23H18ClF2N3O3S

                                                                     F
                                                          HN
                                                                                    O O
                                                      N                              S
                                                                                   N               CH3
                                                                                   H
                                                                     O     F




                                             Cl



 verubulinum
 verubulin                                   N-(4-methoxyphenyl)-N,2-dimethylquinazolin-4-amine

 vérubuline                                  N-(4-méthoxyphényl)-N,2-diméthylquinazolin-4-amine

 verubulina                                  N,2-dimetil-N-(4-metoxifenil)quinazolin-4-amina

                                             C17H17N3O

                                                      CH3
                                                                               OCH3
                                                  N       N

                                                               N
                                                               CH3




                                                                                                                             93
Recommended INN: List 65                             WHO Drug Information, Vol. 25, No. 1, 2011


 vidofludimusum
 vidofludimus              2-[N-(3-fluoro-3'-methoxy[1,1'-biphenyl]-4-yl)carbamoyl]cyclopent-
                           1-ene-1-carboxylic acid

 vidofludimus              acide 2-[N-(3-fluoro-3'-méthoxy[1,1'-biphényl]-
                           4-yl)carbamoyl]cyclopent-1-ène-1-carboxylique

 vidofludimús              ácido 2-[N-(3-fluoro-3'-metoxi[1,1'-bifenil]-4-il)carbamoil]ciclopent-
                           1-eno-1-carboxílico

                           C20H18FNO4

                                       F
                                             H
                                             N
                                                          CO2H
                                                 O




                              OCH3



 vilanterolum
 vilanterol                4-{(1R)-2-[(6-{2-[(2,6-dichlorophenyl)methoxy]ethoxy}hexyl)amino]-
                           1-hydroxyethyl}-2-(hydroxymethyl)phenol

 vilantérol                4-{(1R)-2-[(6-{2-[(2,6-dichlorophényl)méthoxy]éthoxy}hexyl)amino]-
                           1-hydroxyéthyl}-2-(hydroxyméthyl)phénol

 vilanterol                4-{(1R)-2-[(6-{2-[(2,6-diclorofenil)metoxi]etoxi}hexil)amino]-
                           1-hidroxietil}-2-(hidroximetil)fenol

                           C24H33Cl2NO5

                                                                                   Cl
                                        H OH
                                                 H
                                                 N                             O
                                                                     O
                                                                                        Cl
                           HO

                                      OH




 vipadenantum
 vipadenant                3-[(4-amino-3-methylphenyl)methyl]-7-(furan-2-yl)-
                           3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine

 vipadénant                3-[(4-amino-3-méthylphényl)méthyl]-7-(furan-2-yl)-
                           3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine

 vipadenant                3-[(4-amino-3-metilfenil)metil]-7-(furan-2-l)-3H-[1,2,3]triazolo[4,5-
                           d]pirimidin-5-amina




94
WHO Drug Information, Vol. 25, No. 1, 2011                                                            Recommended INN: List 65


                                             C16H15N7O

                                                                               CH3
                                                    O
                                                          N N                           NH2

                                                               N
                                                    N
                                                          N

                                                    H2N



 vismodegibum
 vismodegib                                  2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-
                                             4-(methanesulfonyl)benzamide

 vismodégib                                  2-chloro-N-[4-chloro-3-(pyridin-2-yl)phényl]-
                                             4-(méthylsulfonyl)benzamide

 vismodegib                                  2-cloro-N-[4-cloro-3-(piridin-2-il)fenil]-4-(metanosulfonil)benzamida

                                             C19H14Cl2N2O3S

                                                 O O
                                                  S
                                             H3 C
                                                                       H
                                                                       N
                                                                                              N
                                                          Cl       O
                                                                                         Cl



 vorapaxarum
 vorapaxar                                   ethyl [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-{(1E)-2-[5-(3-
                                             fluorophenyl)pyridine-2-yl]ethen-1-yl}-1-methyl-
                                             3-oxododecahydronaphtho[2,3-c]furan-6-yl]carbamate

 vorapaxar                                   [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-{(1E)-2-[5-(3-fluorophényl)pyridin-
                                             2-yl]éthén-1-yl}-1-méthyl-3-oxododécahydronaphto[2,3-c]furan-
                                             6-yl]carbamate d'éthyle

 vorapaxar                                   [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-{(1E)-2-[5-(3-fluorofenil)piridin-
                                             2-il]eten-1-il}-1-metil-3-oxododecahidronafto[2,3-c]furan-
                                             6-il]carbamato de etilo

                                             C29H33FN2O4

                                                                                    O
                                                                           O
                                                               H3C                   H
                                                                   H
                                                                       H        H        H
                                                          N
                                                                                                  O
                                                                           H                  H
                                                                                              N       O   CH3
                                                                                              H


                                                F




                                                                                                                            95
Recommended INN: List 65                                                    WHO Drug Information, Vol. 25, No. 1, 2011




                            AMENDMENTS TO PREVIOUS LISTS
                    MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
                        MODIFICACIONES A LAS LISTAS ANTERIORES


Recommended International Non Proprietary Names (Rec. INN): List 6
(WHO Chronicle, Vol. 20, No. 11, 1966)

         dalanatum insulinum
p. 424   dalanated insulin             replace the description by the following

                                       an insulin derivative prepared by the removal of the C-terminal alanine from the
                                       B chain of insulin


Recommended International Non Proprietary Names (Rec. INN): List 31
Denominations communes internationales recommandées (DCI Rec.): Liste 31
Denominaciones Comunes Internacionales Recomandadas (DCI Rec.): Lista 31
(WHO Drug Information, Vol. 5, No. 3, 1991)

p. 13     delete/supprimer/suprimáse   insert/insérer/insertese
          suplatastum tosilas          suplatasti tosilas

Recommended International Non Proprietary Names (Rec. INN): List 51
Denominations communes internationales recommandées (DCI Rec.): Liste 51
Denominaciones Comunes Internacionales Recomandadas (DCI Rec.): Lista 51
(WHO Drug Information, Vol. 18, No. 1, 2004)

p. 102    delete/supprimer/suprimáse   insert/insérer/insertese
          ralfinamidum                 priralfinamidum
          ralfinamide                  priralfinamide
          ralfinamide                  priralfinamide
          ralfinamida                  priralfinamida

Recommended International Non Proprietary Names (Rec. INN): List 59
Denominations communes internationales recommandées (DCI Rec.): Liste 59
Denominaciones Comunes Internacionales Recomandadas (DCI Rec.): Lista 59
(WHO Drug Information, Vol. 22, No. 1, 2008)

p. 66     delete/supprimer/suprimáse   insert/insérer/insertese
          sergliflozinum etabonas      sergliflozini etabonas

Recommended International Non Proprietary Names (Rec. INN): List 63
Denominations communes internationales recommandées (DCI Rec.): Liste 63
Denominaciones Comunes Internacionales Recomandadas (DCI Rec.): Lista 63
(WHO Drug Information, Vol. 24, No. 1, 2010)

p. 56    fonturacetamum
         fonturacetam                  replace the chemical name by the following
         fonturacétam                  remplacer le nom chimique par le suivant
         fonturacetam                  sustitúyase el nombre químico por el siguiente
                                       rac-2-(2-oxo-4-phenylpyrolidin-1-yl)acetamide
                                       rac-2-(2-oxo-4-phénylpyrolidin-1-yl)acétamide
                                       rac-2-(4-fenil-2-oxopirolidin-1-il)acetamida


96
WHO Drug Information, Vol. 25, No. 1, 2011                                                    Recommended INN: List 65




p. 74    sifalimumabum
         sifalimumab                    replace the description by the following
         sifalimumab                    remplacer la description par la suivante
         sifalimumab                    sustitúyase la descripción por la siguiente

                                        immunoglobulin G1-kappa, anti-[Homo sapiens interferon alpha (IFN-alpha)],
                                        Homo sapiens monoclonal antibody;
                                        gamma1 heavy chain (1-446) [Homo sapiens VH (IGHV1-18*01 (95.90%) -
                                        (IGHD)-IGHJ4*01) [8.8.9] (1-116) –IGHG1*03 CH1 R120>K (213) (117-446)],
                                        (219-213')-disulfide with kappa light chain (1'-215') [Homo sapiens V-KAPPA
                                        (IGKV3-20*01 (99.00%) –IGKJ1*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')];
                                        (225-225'':228-228'')-bisdisulfide dimer

                                        immunoglobuline G1-kappa, anti-[Homo sapiens interféron alpha (IFN-alpha)],
                                        Homo sapiens anticorps monoclonal;
                                        chaîne lourde gamma1 (1-446) [Homo sapiens VH (IGHV1-18*01 (95.90%) -
                                        (IGHD)-IGHJ4*01) [8.8.9] (1-116) –IGHG1*03 CH1 R120>K (213) (117-446)],
                                        (219-215')-disulfure avec la chaîne légère kappa (1'-215') [Homo sapiens V-
                                        KAPPA (IGKV3-20*01 (99.00%) –IGKJ1*01) [7.3.9] (1'-108') -IGKC*01 (109'-
                                        215')]; dimère (225-225'':228-228'')-bisdisulfure

                                        inmunoglobulina G1-kappa, anti-[interferón alfa (IFN-alfa) de Homo
                                        sapiens], anticuerpo monoclonal de Homo sapiens;
                                        cadena pesada gamma1 (1-446) [Homo sapiens VH (IGHV1-18*01
                                        (95.90%) -(IGHD)-IGHJ4*01) [8.8.9] (1-116) –IGHG1*03 CH1
                                        R120>K (213) (117-446)], (219-215')-disulfuro con la cadena ligera kappa
                                        (1'-215') [Homo sapiens V-KAPPA (IGKV3-20*01 (99.00%) –
                                        IGKJ1*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; dímero (225-
                                        225'':228-228'')-bisdisulfuro




Recommended International Non Proprietary Names (Rec. INN): List 64
Denominations communes internationales recommandées (DCI Rec.): Liste 64
Denominaciones Comunes Internacionales Recomandadas (DCI Rec.): Lista 64
(WHO Drug Information, Vol. 24, No. 3, 2010)

p. 260   afatinibum
         afatinib                       replace the chemical name by the following
         afatinib                       remplacer le nom chimique par le suivant
         afatinib                       sustitúyase el nombre químico por el siguiente

                                        (2E)-N-[4-(3-chloro-4-fluoroanilino)-7-{[(3S)-oxolan-
                                        3-yl]oxy}quinazolin-6-yl]-4-(dimethylamino)but-2-enamide

                                        (2E)-N-[4-(3-chloro-4-fluoroanilino]-7-{[(3S)-oxolan-
                                        3-yl]oxy}quinazolin-6-y]-4-(diméthylamino)but-2-énamide

                                        (2E)-N-[4-(3-cloro-4-fluoroanilino)-7-{[(3S)-oxolan-
                                        3-il]oxi}quinazolin-6-il]-4-(dimetilamino)but-2-enamida




                                                                                                                      97
Recommended INN: List 65                                                   WHO Drug Information, Vol. 25, No. 1, 2011




p. 279   sotaterceptum
         sotatercept                  replace the description by the following
         sotatercept                  remplacer la descriptions par la suivante
         sotatercept                  sustitúyase la descripción por la siguiente

                                      fusion protein for immune applications (FPIA) comprising Homo sapiens
                                      ACVR2A (activin receptor type 2A, activin receptor type IIA) fragment fused
                                      with Homo sapiens immunoglobulin G1 Fc fragment;
                                      Homo sapiens ACVR2A, 21-135 precursor fragment (1-115) -threonyl-triglycyl
                                      linker (116-119) -gamma1 chain H-CH2-CH3 fragment (120-344) [Homo
                                      sapiens IGHG1*03 hinge (120-127), CH2, A115>V (227) (128-237), CH3 (238-
                                      344)]; (123-123':126-126')-bisdisulfide dimer

                                      protéine de fusion pour applications immunitaires (FPIA) comprenant un
                                      fragment d’Homo sapiens ACVR2A (récepteur type 2A de l’activine, récepteur
                                      type IIA de l’activine) fusionné au fragment Fc de l’Homo sapiens
                                      immunoglobuline G1;
                                      fragment précurseur 21-135 de Homo sapiens ACVR2A (1-115) -linker
                                      thréonyl-triglycyl (116-119) -fragment H-CH2-CH3 de chaîne gamma1 (120-
                                      344) [Homo sapiens IGHG1*03 charnière (120-127), CH2, A115>V (227) (128-
                                      237), CH3 (238-344)]; dimère (123-123':126-126')-bisdisulfure

                                      proteína de fusión para aplicaciones inmunitarias (FPIA) que comprende un
                                      fragmento de ACVR2A (receptor tipo 2A de la activina, receptor tipo IIA de la
                                      activina) de Homo sapiens fusionado al fragmento Fc de la inmunoglobulina G1
                                      de Homo sapiens;
                                      fragmento precursor 21-135 de ACVR2A de Homo sapiens (1-115)-conector
                                      treonil-triglicil (116-119) -fragmento H-CH2-CH3 de cadena gamma1 (120-344)
                                      [Homo sapiens IGHG1*03 bisagra(120-127), CH2, A115>V (128-237), CH3
                                      (238-344)]; dímero (123-123':126-126')-bisdisulfuro

# Electronic structure available on Mednet: http://mednet.who.int/
# Structure electronique disponible sur Mednet: http://mednet.who.int/
# Estructura electrónica disponible en Mednet: http://mednet.who.int/

* "INN for pharmaceutical substances: Names for radicals, groups & others" document available at /
document disponible à / documento disponible en :
http://www.who.int/medicines/services/inn/publication/en/index.html



 Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales
 The text of the Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical
 Substances and General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical
 Substances will be reproduced in proposed INN lists only.
 Les textes de la Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les
 substances pharmaceutiques et des Directives générales pour la formation de dénominations communes internationales
 applicables aux substances pharmaceutiques seront publiés seulement dans les listes des DCI proposées.
 El texto de los Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias
 farmacéuticas y de los Principios generales de orientación para formar denominaciones comunes internacionales para
 sustancias farmacéuticas aparece solamente en las listas de DCI propuestas.




98
